Protocol  COL.AOM.2013.002 
 
Page 1 of 76 
Final Protocol: 29 July 2013 1 TITLE PAGE ARIPI[INVESTIGATOR_123094], ABILIFY MAINTENA™ CLINICAL PROTOCOL A Randomized, Open-Label, Parallel-Group, Study of the Impact of Aripi[INVESTIGATOR_123095]. COL.AOM.2013.002 G-Port No.  CONFIDENTIAL – PROPRIETARY INFORMATION Drug Development Phase: 4   Principal Investigator: [INVESTIGATOR_123096]-Todd, PhD Professor of Psychiatry Director of Imaging The Brain Institute Phone:  [PHONE_2792]    Otsuka Contact: [INVESTIGATOR_97332] N. Legacy, MD Associate Director - CNS Medical Affairs Otsuka America Pharmaceuticals, Inc. Phone:  [PHONE_2793]  Fax:  [PHONE_2794]   Immediately Reportable Event Clinical Safety and Pharmacovigilance Otsuka Pharmaceutical Development & Commercialization, Inc. Khaled Bannout, MD Phone:  [PHONE_2795] Fax:  [PHONE_2796]   Issue Date: 29 July 2013   
Protocol  COL.AOM.2013.002 
 
Page 2 of 76 
Final Protocol: 29 July 2013 2 CLINICAL PROTOCOL SYNOPSIS Name [CONTACT_790]:  The Brain Institute Name [CONTACT_35215]:  Abilify Maintena™, aripi[INVESTIGATOR_123097]: A Randomized, Open-Label, Parallel-Group, Study of the Impact of Aripi[INVESTIGATOR_123098]: 4 Treatment Indication:  Schizophrenia Objectives: The primary objective of the study is: • To determine if there are differences in prefrontal white matter fractional anisotrophy (FA) in subjects with schizophrenia after [ADDRESS_138593] of care (SOC) oral antipsychotic medications.  The secondary objectives of the study are: • To determine if there are differences in water bound pool fraction (BPF) in prefrontal white matter in subjects with schizophrenia after 6 and 12 months of treatment with aripi[INVESTIGATOR_123099]. • To determine if proton metabolites, specifically gamma-aminobutyric acid (GABA), glutamine, and glutamate, are altered in subjects with schizophrenia after 6 and 12 months of treatment with aripi[INVESTIGATOR_123100]. • To determine if there are differences in regional white matter and gray matter volume in subjects with schizophrenia after 6 and 12 months of treatment with aripi[INVESTIGATOR_123100]. • To determine the effect on clinical and behavioral assessments after 12 months with aripi[INVESTIGATOR_123101]. The exploratory objective of the study is: • To determine if there is a demonstrated association between clinical and neurocognitive variables and FA, BPF, and proton metabolite concentrations in subjects with schizophrenia receiving SOC oral antipsychotic medications or once monthly aripi[INVESTIGATOR_4253]. 
Protocol  COL.AOM.2013.002 
 
Page 3 of 76 
Final Protocol: 29 July 2013 Name [CONTACT_790]:  The Brain Institute Name [CONTACT_35215]:  Abilify Maintena™, aripi[INVESTIGATOR_123102]: This is a Phase 4, randomized, open-label, parallel-group study designed to assess the clinical and biological effects of 12 months of treatment with long-acting intramuscular (IM) aripi[INVESTIGATOR_123103], and changes on magnetic resonance imaging (MRI) scans in subjects with schizophrenia compared with SOC oral antipsychotic medications and compared with a healthy control group.  A total of 80 subjects are planned to be enrolled in the study in a 3:1 subjects with schizophrenia:control ratio, to allow for an expected 60 completed subjects:  approximately 45 subjects with Diagnostic and Statistical Manual, Fourth Edition – Text Revision (DSM-IV-TR) schizophrenia, and approximately 15 healthy control subjects.  Attempts will be made to age-, gender-, and education-match the healthy control group with the schizophrenia group.  Prospective subjects will undergo a thorough psychiatric and clinical screening phase, including a physical and neurological exam, 12-lead electrocardiogram (ECG), and baseline clinical laboratory testing.   After screening, subjects with schizophrenia will be randomized in a 2:1 aripi[INVESTIGATOR_123104]:oral SOC antipsychotics ratio to the aripi[INVESTIGATOR_123105].  Subjects with schizophrenia who are randomized to the aripi[INVESTIGATOR_123106] a medication washout and a conversion (Phase A) to oral aripi[INVESTIGATOR_123107].  In addition, any subject who is still taking a prohibited medication will enter Phase A for the appropriate washout.  All subjects with schizophrenia will proceed to Phase B (Stabilization) directly after screening, or after Phase A if conversion to oral aripi[INVESTIGATOR_123108].  Once stable on SOC oral antipsychotic medications for 2 consecutive visits, the subjects will proceed into Phase C (Treatment).  Control subjects will also enter Phase C.  All subjects with schizophrenia will undergo neuropsychological testing, clinical ratings, and multimodal MRI acquisition.  The MRI scanning protocol includes high-resolution MRI, diffusion tensor (DT)-MRI, water-BPF, and magnetic resonance spectroscopy (MRS). Neuropsychological testing, clinical ratings, and multimodal MRI acquisitions will be performed after 6 and 12 months of treatment.  The subjects will be assessed at regularly scheduled visits according to the schedule of assessments (Table 4 through Table 7).  Six and 12-month MRI indices in subjects receiving once monthly aripi[INVESTIGATOR_123109], the data from subjects with schizophrenia who are receiving SOC oral antipsychotic medications, and the healthy control subjects.   Instruments for the assessment of clinical and behavioral changes are: Clinical assessments including suicidality, mood, extrapyramidal side effects (EPS), and adverse drug effects are:  Abnormal Involuntary Movement Scale (AIMS), Barnes Akathesia Rating Scale (BARS), Clinical and Global Impression – Improvement (CGI-I), Clinical and Global Impression – Severity (CGI-S), Clinical and Global Impression -  Severity of Suicidality (CGI-SS), Columbia Suicide Severity Rating Scale (C-SSRS), Hamilton Anxiety Scale (HAM-A), Hamilton Depression Rating Scale (HAM-D), Medication Adherence Questionnaire (MAQ), Monitoring of Side Effects Scale (MOSES), Positive and Negative Symptom Scale (PANSS), Profile of Mood States (POMS), and Simpson Angus Scale (SAS).  
Protocol  COL.AOM.2013.002 
 
Page 4 of 76 
Final Protocol: 29 July 2013 Name [CONTACT_790]:  The Brain Institute Name [CONTACT_35215]:  Abilify Maintena™, aripi[INVESTIGATOR_123110]: In addition to completion of formal rating scales used to assess suicidal ideation and behaviors, suicidal symptomology will be monitored using structured interview questions and follow-up queries.   Neuropsychological testing will include:  The CogState tests which include Simple Reaction Time, Choice Reaction Time, One-back Working memory, Two-back Working Memory, and Set Shifting. Other neuropsychological tests will be the TrailMaking Test, Tower of London, Continuous Performance Test (CPT) and the Wisconsin Card Sorting Test (WCST). Functional assessments will include:  Functional Assessment Test (FAST), Quality of Life Scale (QOLS), Social and Occupational Functioning Assessment Scale (SOFAS), and Life Functioning Questionnaire (LFQ). Healthy control subjects will not receive any investigational medicinal product (IMP); however these subjects will undergo all of the study procedures for comparison with the subjects with schizophrenia. Compliance with SOC drug will be managed using medication possession ratio (MPR) for prescription refills and the MAQ. Subject Population: A total of 80 subjects, aged 18 to 35 years will be enrolled to provide for an approximate 60 subjects who complete the study, 45 subjects with DSM-IV-TR schizophrenia and 15 healthy volunteers  Study Drug, Dose, Formulation, Mode of Administration: Aripi[INVESTIGATOR_4253], administered once monthly via gluteal IM injection, as outlined in the product labeling. Oral antipsychotics – (SOC), which includes but is not limited to per oral (PO) administration of the following drugs as prescribed for the treatment of schizophrenia: • aripi[INVESTIGATOR_4253] (Abilify®) 10 to 30 mg daily  • risperidone (Risperdal®) 2 to 8 mg daily • lurasidone HCl (Latuda®) 40 to 160 mg daily • quetiapi[INVESTIGATOR_123111] (Seroquel®) 300 to 800 mg daily • olanzapi[INVESTIGATOR_050] (Zyprexa®) 10 to 30 mg daily • ziprasidone HCl (Geodon®) [ADDRESS_138594] labeling. 
Protocol  COL.AOM.2013.002 
 
Page 5 of 76 
Final Protocol: 29 July 2013 Name [CONTACT_790]:  The Brain Institute Name [CONTACT_35215]:  Abilify Maintena™, aripi[INVESTIGATOR_123112]: Primary Outcome Variables: Efficacy:  The primary endpoint is FA by [CONTACT_123251]-MRI.  Secondary Outcome Variables: Efficacy:  The secondary endpoints are: • Volumes by [CONTACT_5019]-resolution MRI • Water-BPF by [CONTACT_9268] • Schizophrenia-related instrument scores including suicidality (CGI-SS and C-SSRS), clinical assessment (CGI-I, GAF), symptomology (CGI-I, CGI-S, HAM-A, HAM-D, PANSS, POMS), medication adherence (MAQ, MPR), neuropsychological assessment (Simple Reaction Time, Choice Reaction Time, One-back Working Memory, Set Shifting, TrailMaking Test, Tower of London, CPT, WCST), functional outcomes (FAST, QOLS, SOFAS, LFQ, Hollignshead Index), and side effects (MOSES) • Proton metabolite measurements by [CONTACT_123252]: The clinical trial duration is expected to be approximately 2 years.  For subjects who do not require conversion to aripi[INVESTIGATOR_4253], the study duration including screening, stabilization, and the treatment phase is expected to be 13 months. For subjects who will require conversion to oral aripi[INVESTIGATOR_4253], the duration is expected to be 14.5 months.  
Protocol  COL.AOM.2013.002 
 
Page 6 of 76 
Final Protocol: [ADDRESS_138595] OF APPENDICES ................................................... Error! Bookmark not defined.	
  [ADDRESS_138596] OF ABBREVIATIONS AND DEFINITIONS OF TERMS ................................... 11	
  5	
  ETHICS ............................................................................................................................. 13	
  5.1	
  Informed consent ................................................................................................... 13	
  6	
  INVESTIGATORS AND STUDY PERSONNEL ........................................................... 14	
  7	
  INTRODUCTION ............................................................................................................. 15	
  7.1	
  Novel approaches to Understanding Brain Changes Associated with Medications ........................................................................................................... 15	
  7.2	
  ABILIFY® (aripi[INVESTIGATOR_4253]) ........................................................................................ 17	
  7.3	
  Relevant Nonclinical Studies ................................................................................ 17	
  7.4	
  Relevant Clinical Studies ...................................................................................... 18	
  7.4.1	
  Schizophrenia Studies with Oral Aripi[INVESTIGATOR_4253] .......................................... 18	
  7.4.2	
  Agitation Studies with Injectable Aripi[INVESTIGATOR_4253] ......................................... 19	
  7.4.3	
  Clinical Studies in Schizophrenia with Aripi[INVESTIGATOR_123113] .......................... 19	
  7.4.4	
  Known and Potential Risks and Benefits .................................................. 20	
  7.5	
  Study Rationale ..................................................................................................... 22	
  8	
  STUDY OBJECTIVES ..................................................................................................... 23	
  8.1	
  Primary Objective(s) ............................................................................................. 23	
  8.2	
  Secondary Objective(s) ......................................................................................... 23	
  8.3	
  Exploratory Objective(s) ....................................................................................... 23	
  9	
  INVESTIGATIONAL PLAN ........................................................................................... 24	
  9.1	
  Overall Study Design and Plan .............................................................................. 24	
  9.1.1	
  Screening Period ........................................................................................ 27	
  9.1.2	
  Baseline ..................................................................................................... 28	
  9.1.3	
  Randomization ........................................................................................... 29	
  [IP_ADDRESS]	
  Overall Treatment ................................................................. 29	
  [IP_ADDRESS]	
  Phase A – Conversion ............................................................ 29	
  [IP_ADDRESS]	
  Phase B – Stabilization .......................................................... 30	
  [IP_ADDRESS]	
  Phase C – Treatment ............................................................. 30	
  9.1.4	
  Follow-Up Period ...................................................................................... 30	
  9.2	
  Discussion of Study Design, Including Choice of Control Groups ....................... 30	
  9.3	
  Selection of Study Population ............................................................................... 31	
  9.3.1	
  Inclusion Criteria ....................................................................................... 31	
  [IP_ADDRESS]	
  Inclusion Criteria for All Subjects ........................................... 31	
  [IP_ADDRESS]	
  Inclusion Criteria for Subjects with Schizophrenia ................. 31	
  9.3.2	
  Exclusion Criteria ...................................................................................... 32	
  [IP_ADDRESS]	
  Exclusion Criteria All Subjects ............................................... 32	
  
Protocol  COL.AOM.2013.002 
 
Page 7 of 76 
Final Protocol: 29 July 2013 [IP_ADDRESS]	
  Exclusion Criteria for Subjects with Schizophrenia ................ 32	
  9.3.3	
  Removal of Subjects From Therapy or Assessment .................................. 33	
  [IP_ADDRESS]	
  Entire Study or Treatment Arm(s) ........................................... 33	
  [IP_ADDRESS]	
  Individual Center ..................................................................... 33	
  [IP_ADDRESS]	
  Individual Subject .................................................................... 33	
  9.4	
  Treatments ............................................................................................................. 34	
  9.4.1	
  Treatments Administered .......................................................................... 34	
  [IP_ADDRESS]	
  Dosage Adjustments for Missed Doses of Aripi[INVESTIGATOR_123114] .......................................................................... [ADDRESS_138597](s) .................................... 35	
  9.4.3	
  Method of Assigning Subjects to Treatment Groups ................................ 35	
  9.4.4	
  Blinding ..................................................................................................... 35	
  9.4.5	
  Prohibited Medication ............................................................................... 35	
  9.4.6	
  Treatment Compliance .............................................................................. 36	
  9.4.7	
  Accountability ........................................................................................... 36	
  9.5	
  Study Assessments ................................................................................................ 37	
  9.5.1	
  Assessments ............................................................................................... 37	
  [IP_ADDRESS]	
  Demographics .......................................................................... 37	
  [IP_ADDRESS]	
  Screening Assessments ............................................................ 38	
  [IP_ADDRESS]	
  Safety Assessments ................................................................. 38	
  [IP_ADDRESS].1	
  Clinical Laboratory Tests ............................................ 38	
  [IP_ADDRESS].2	
  Physical Examination .................................................. 39	
  [IP_ADDRESS].3	
  ECG Assessments ........................................................ 39	
  [IP_ADDRESS]	
  Adverse Events and Other Events of Interest .......................... 39	
  [IP_ADDRESS]	
  Serious Adverse Events and Other Events of Interest ............. 42	
  [IP_ADDRESS]	
  Other Safety Assessments ....................................................... 43	
  [IP_ADDRESS].1	
  Injection Site Evaluation ............................................. 43	
  [IP_ADDRESS].[ADDRESS_138598] Circumference ............... 43	
  [IP_ADDRESS].3	
  Vital Signs ................................................................... 43	
  [IP_ADDRESS].4	
  Schizophrenia Assessments ......................................... 43	
  [IP_ADDRESS].5	
  Suicidality .................................................................... 44	
  [IP_ADDRESS].[ADDRESS_138599] ............................................................ 45	
  [IP_ADDRESS].7	
  Urine Screen for Drugs of Abuse ................................ 45	
  [IP_ADDRESS].8	
  Monitoring of Side Effects Scale (MOSES) ............... 46	
  [IP_ADDRESS]	
  Efficacy Assessments – Clinical Outcome .............................. 46	
  [IP_ADDRESS].1	
  Clinical Global Impression – Improvement ................ 46	
  [IP_ADDRESS].2	
  Clinical Global Impression – Severity ........................ 46	
  [IP_ADDRESS].3	
  Positive and Negative Syndrome Scale (PANSS) ...................................................................... 46	
  [IP_ADDRESS]	
  Efficacy Assessments – Extrapyramidal Symptoms ............... 47	
  [IP_ADDRESS].1	
  Abnormal Involuntary Movement Scale (AIMS) ........ 47	
  [IP_ADDRESS].2	
  Barnes Akathisia Rating Scale (BARS) ...................... 47	
  [IP_ADDRESS].3	
  Simpson Angus Scale (SAS) ....................................... 47	
  [IP_ADDRESS]	
  Efficacy Assessments – Mood ................................................. 47	
  [IP_ADDRESS].1	
  The Hamilton Anxiety Scale (HAM-A) ...................... 47	
  
Protocol  COL.AOM.2013.002 
 
Page 8 of 76 
Final Protocol: 29 July 2013 [IP_ADDRESS].2	
  The Hamilton Depression Rating Scale (HAM-D) ................................................................................. 48	
  [IP_ADDRESS].3	
  The Profile of Mood States (POMS) ........................... 48	
  [IP_ADDRESS]	
  Efficacy Assessments – Medication Adherence ...................... 48	
  [IP_ADDRESS].1	
  Medication Adherence Questionnaire (MAQ) ............ 48	
  [IP_ADDRESS].2	
  Medication Possession Ratio (MPR) ........................... 48	
  [IP_ADDRESS]	
  Other Assessments ................................................................... 48	
  [IP_ADDRESS].1	
  Neuropsychological Measures ..................................... 48	
  [IP_ADDRESS].2	
  Functional Outcomes and Quality of Life ................... 50	
  [IP_ADDRESS]	
  Pharmacokinetic/Pharmacodynamic Assessments .................. [ADDRESS_138600] ....................................................................................... 59	
  [IP_ADDRESS]	
  Reporting of Serious Adverse Events ...................................... 59	
  [IP_ADDRESS]	
  Immediately Reportable Events (IRE) .................................... 60	
  [IP_ADDRESS]	
  Reporting of Pregnancy and Exposure to Study Drug Through Breastfeeding ............................................................ 61	
  [IP_ADDRESS]	
  Reporting of Safety Information and Other Events of Interest ..................................................................................... 61	
  [IP_ADDRESS]	
  Regulatory Reporting of Adverse Events ................................ 63	
  9.5.5	
  Database Reconciliation ............................................................................ 63	
  9.5.6	
  Completion/Discontinuation of Subjects ................................................... 63	
  9.5.7	
  Confirmation of Medical Care by [CONTACT_3550] ............................... 64	
  9.6	
  Data Quality Assurance ......................................................................................... 64	
  9.6.1	
  Monitoring ................................................................................................. 64	
  9.6.2	
  Auditing ..................................................................................................... 64	
  9.6.3	
  Data Collection Duration ........................................................................... 64	
  9.7	
  Statistical Methods ................................................................................................ 64	
  9.7.1	
  Statistical and Analytical Plans ................................................................. 64	
  [IP_ADDRESS]	
  Primary Endpoint(s) ................................................................ 65	
  [IP_ADDRESS]	
  Exploratory Endpoint(s) .......................................................... 65	
  [IP_ADDRESS]	
  Definitions of Analysis Sets .................................................... 65	
  [IP_ADDRESS]	
  Subject Disposition .................................................................. 65	
  [IP_ADDRESS]	
  Demographic and Other Baseline Characteristics ................... 65	
  [IP_ADDRESS]	
  Prior and Concomitant Therapy .............................................. 66	
  [IP_ADDRESS]	
  Safety Analyses ....................................................................... 66	
  [IP_ADDRESS].1	
  Extent of Exposure ...................................................... 66	
  [IP_ADDRESS].2	
  Adverse Events ............................................................ 66	
  [IP_ADDRESS].3	
  Laboratory Values ....................................................... 67	
  [IP_ADDRESS].4	
  Physical Examination and Vital Signs ........................ 67	
  [IP_ADDRESS].5	
  Electrocardiograms ...................................................... 67	
  [IP_ADDRESS].6	
  Other Safety Analyses ................................................. 68	
  [IP_ADDRESS]	
  Efficacy Analyses .................................................................... 68	
  [IP_ADDRESS].1	
  Primary Efficacy Analysis ........................................... 68	
  [IP_ADDRESS].2	
  Secondary Efficacy Analyses ...................................... 68	
  
Protocol  COL.AOM.2013.002 
 
Page 9 of 76 
Final Protocol: 29 July 2013 [IP_ADDRESS].3	
  Exploratory Efficacy Analyses .................................... 68	
  [IP_ADDRESS]	
  Pharmacokinetic/Pharmacodynamic Analyses ........................ 68	
  [IP_ADDRESS].1	
  Pharmacokinetic Analyses ........................................... 68	
  [IP_ADDRESS].2	
  Pharmacodynamic Analyses ........................................ 68	
  9.7.2	
  Determination of Sample Size ................................................................... 68	
  9.7.3	
  Interim Analysis ........................................................................................ 69	
  [IP_ADDRESS]	
  Data Safety Monitoring Board ................................................ 69	
  [IP_ADDRESS].[ADDRESS_138601] ........................................................................... 69	
  [IP_ADDRESS].2	
  Monitoring of Data Quality by [CONTACT_4318] .................. 69	
  9.7.4	
  Other Statistical/Analytical Issues ............................................................. [ADDRESS_138602] ........................................................................................................... 73	
  12	
  APPENDICES ................................................ ERROR! BOOKMARK NOT DEFINED.	
    
Protocol  COL.AOM.2013.002 
 
Page 10 of 76 
Final Protocol: [ADDRESS_138603] OF IN-TEXT TABLES Table 1:	
  Estimated Enrollment - Subjects Completed Per Year .......................................... 31	
  Table 2:	
  Prohibited and Restricted Medications .................................................................. 36	
  Table 3.	
  Safety Clinical Laboratory Tests ........................................................................... 39	
  Table 4	
  Schedule of Assessments – Phase A – Screening and Conversion Phase ............. 53	
  Table 5:	
  Schedule of Assessments Phase B – Oral Stabilization Phase .............................. 55	
  Table 6:	
  Schedule of Assessments Phase C - Treatment Phase ........................................... 57	
  Table 7:	
  Neuropsychological Measures for the Treatment Phase (Phase C) ....................... [ADDRESS_138604] OF IN-TEXT FIGURES Figure 1	
  Study Schematic .................................................................................................... 26	
   
Protocol  COL.AOM.2013.002 
 
Page 11 of 76 
Final Protocol: [ADDRESS_138605] CRF case report form C-SSRS Columbia Suicide Severity Rating Scale DCF data clarification form DSM-IV-TR Diagnostic and Statistical Manual, Fourth Edition – Text Revision DSMB Data Safety Monitoring Board DT diffusion tensor EC Ethics Committee ECG electrocardiogram EPI [CONTACT_26142]-planar imaging EPS extrapyramidal side effects FA fractional anisotrophy FAST Functional Assessment Test FDA Food and Drug Administration fMRI functional magnetic resonance imaging GABA gamma-aminobutyric acid GAF DSM-IV-TR Global Assessment of Functioning GCP Good Clinical Practice GGT gamma glutamyl transferase GLX glutamate/glutamine HAM-A Hamilton Anxiety Scale HAM-D Hamilton Depression Rating Scale 
Protocol  COL.AOM.2013.002 
 
Page 12 of 76 
Final Protocol: [ADDRESS_138606]  
Protocol  COL.AOM.2013.002 
 
Page 13 of 76 
Final Protocol: [ADDRESS_138607] will review and sign the informed consent form (ICF). Written informed consent will be obtained from all subjects (or their guardian or legal representative, as applicable for local laws).  Consent will be documented on a written ICF.  The ICF will be approved by [CONTACT_123253] (IRB) that approves this protocol.  Each ICF will comply with the Food and Drug Administration (FDA) regulations in Title 21 Code of Federal Regulations (CFR) Part 50, International Conference on Harmonisation (ICH), Good Clinical Practices (GCP), and local regulatory requirements.  The investigator agrees to obtain approval from the sponsor of any written ICF used in the study, prior to submission to the IRB. Investigators may discuss study availability and the possibility for entry with a potential subject without first obtaining consent.  However, informed consent must be obtained and documented prior to initiation of any procedures that are performed solely for the purpose of determining eligibility for this study, including withdrawal from current medication(s). Once appropriate essential information has been provided and fully explained in layman’s language to the subject by [CONTACT_093], or a qualified designee, the IRB-approved written ICF will be signed and dated by [CONTACT_123254] (investigator or designee), as well as by [CONTACT_78629].  The subject will receive a copy of the signed informed consent form; the original shall be kept on file by [CONTACT_093]. 
Protocol  COL.AOM.2013.002 
 
Page 14 of 76 
Final Protocol: [ADDRESS_138608], Salt Lake City, UT  [ZIP_CODE]. Principal Investigator: [INVESTIGATOR_60055]-Investigator Deborah Yurgelun-Todd, PhD Professor of Psychiatry University of Utah School of Medicine Director of Cognitive Neuroimaging The Brain Institute [ADDRESS_138609] Room 308 Associate Director, VISN 19 MIRECC  (Mental Illness Research and Clinical Center) Phone:  [PHONE_2792] e-mail:  [EMAIL_2449]  Melissa Lopez-Larson, MD Assistant [CONTACT_58576] of Utah School of Medicine The Brain Institute 383 Colorow Raod Phone:  [PHONE_2797] e-mail:  [EMAIL_2450]    Data Safety Monitoring Board: Laboratory for Drugs of Abuse Testing: Douglas Kondo, MD Assistant [CONTACT_123289] of Utah Reporting of SAEs: [LOCATION_003]MRMC ORP, HRPO  Immediate report:  Phone:  [PHONE_164] e-mail:  [EMAIL_2451] Fax:  [PHONE_165]  Written Follow-up: [LOCATION_003]MRMC Attn:  MCMR-ZB-P [ADDRESS_138610] Salt Lake City, UT [ZIP_CODE] ([PHONE_2798] ([PHONE_2799]  ([PHONE_2800] (fax)  
 
Protocol  COL.AOM.2013.002 
 
Page 15 of 76 
Final Protocol: [ADDRESS_138611] with clear antipsychotic effects and represents a novel treatment development for psychotic disorders.  Aripi[INVESTIGATOR_123115], including partial 5-HT1A agonism, 5-HT2A antagonism, and affinity for the 5-HT2C, 5-HT6, and 5-HT7 receptors.  Aripi[INVESTIGATOR_123116], safe, well tolerated, and has shown efficacy in the treatment of both the positive and negative symptoms of schizophrenia and schizoaffective disorder.  Its unique mechanism of action may account for its sustained efficacy and favorable safety and tolerability profile, including a low risk for extrapyramidal symptoms (EPS), cardiac effects, hyperprolactinemia, weight gain, and other metabolic disturbances.  Despi[INVESTIGATOR_123117]-effect profile of this agent, medication compliance in individuals with schizophrenia is still problematic and may impact symptomatic and cognitive recovery.  Improved adherence to psychotropic treatment via long-acting injectable formulations may therefore lead to greater symptomatic improvements in this patient population, which may be detectible not only clinically but via current neuroimaging techniques as well.  Therefore, the aim of this study is to examine the structural and metabolic effects of long-acting intramuscular (IM) aripi[INVESTIGATOR_123118] (SOC) oral antipsychotic medications in subjects with schizophrenia using magnetic resonance imaging (MRI) techniques and to examine these effects in association with cognitive and clinical measures. Schizophrenia is a chronic illness associated with progressive brain changes over time1.  The process underlying tissue loss has been attributed to the course of the illness.  However, a study in primates found that loss of gray matter in schizophrenia may be related to antipsychotic medications2. In human studies of schizophrenia, volume losses have been reported for typi[INVESTIGATOR_123119]3-5.  A recent investigation of long-acting depot risperidone versus oral risperidone in first-epi[INVESTIGATOR_123120] 6-month trial in the long-acting depot patients, while it declined in those individuals taking oral risperidone.  Interestingly, the increase in white matter was associated with improved cognitive performance.  The authors suggested that the long-acting preparation changed the trajectory of myelination secondary to improved compliance6.  Treatment with long-acting atypi[INVESTIGATOR_123121], including decreased hospi[INVESTIGATOR_123122].  7.1 NOVEL APPROACHES TO UNDERSTANDING BRAIN CHANGES ASSOCIATED WITH MEDICATIONS While conventional magnetic resonance imaging (MRI) allows for adequate visualization of brain structures and the detection of white matter lesions and hyperintensities, white matter tracts are not readily distinguishable.  Diffusion tensor (DT)-MRI is a relatively new MRI modality designed to measure differences in constraints on water diffusion in various types of tissue7.  Diffusion tensor imaging has proven effective for observing the relationship between cognitive deficits and structural connectivity in white matter.  For example, fractional anisotropy (FA), reflective of tissue organization, degree of myelination, and water mobility, has been extensively used to correlate measures of diffusion with cognitive ability8.  In a study of cognitive aging and executive function, Grieve et al. administered a battery of executive tasks and gathered DT-MRI data in a sample of 87 healthy subjects (aged 20 to 73 years) and found a significant negative association between age and average FA values in the frontal, parietal, and temporal lobes9.  
Protocol  COL.AOM.2013.002 
 
Page 16 of 76 
Final Protocol: 29 July 2013 Fractional anisotropy was shown to decrease at a rate of approximately 3% per decade in the prefrontal regions of the frontal lobe.  Additionally, decreased FA was associated with poorer cognitive performance in executive maze and attention-shifting tasks9.  These findings are consistent with earlier correlational work showing a negative association between age and FA values and a positive correlation between FA values and cognitive performance10.  Determining the precise macromolecular content in neural tissue is crucial for accurately investigating white matter changes associated with anomalous brain development in the central nervous system (CNS)11.  Recent imaging modalities, such as DT-MRI, provide useful, potential complementary tools that may aid in this process, but they are not without their limitations.  For instance, DT-MRI indices, which measure the directionality of water diffusion in white matter through measures of FA, apparent diffusion coefficient (ADC) and mean diffusivity (MD), may or may not in fact be indicative of compromised brain tissue.  Furthermore, there is still some disagreement over what exactly FA and ADC measure.  Nevertheless, DT-MRI and other techniques have yielded promising findings, which may be aided by [CONTACT_123255], such as T1 bound pool fraction (BPF).  Bound pool fraction, a T1 measurement, may hold particular utility in the assessment of white matter tissue integrity, as it is a more direct measure of myelin content12.  There is already convincing evidence, including some from the demyelinating disease, multiple sclerosis, that BPF is directly linked to the composition and density of myelin13-15, a dielectric material that enables rapid and efficient conduction of neural signals16-18.  Relevant to this proposal, Soellinger and colleagues’ recent work demonstrated that, at [ADDRESS_138612], constitute complementary findings, which will clarify the mechanisms underlying white matter changes associated with the atypi[INVESTIGATOR_123123], aripi[INVESTIGATOR_4253]. Magnetic resonance spectroscopy (MRS) methods allow identification and quantification of chemical compounds in tissue.  The application of proton (1H) MRS is widely used for in vivo measurement of human brain chemistry because nearly all metabolites contain protons, allowing for a large number of important neurochemicals to be detected and measured.  Proton (1H) MRS can measure cerebral concentrations of N-acetyl aspartate (NAA), choline (Cho)-containing compounds, glutamate/glutamine (Glx), myo-inositol (mI), lactate, and gamma-aminobutyric acid (GABA), which plays a central role in maintaining inhibitory function19.  The primary inhibitory neurotransmitter, GABA, is distributed ubiquitously throughout the mammalian CNS.  Altered GABAergic neurotransmission has been implicated in a wide range of human CNS disorders including epi[INVESTIGATOR_002], schizophrenia, anxiety, and substance abuse disorders20.  The pharmacological manipulation of GABAergic neurotransmission is a common target for many of these disorders and Proton (1H) MRS approaches have successfully demonstrated normalized post-treatment GABA levels in depression21, epi[INVESTIGATOR_002]22, and substance abuse disorders23.  To date, there have been no studies on the relationship between brain GABA levels and aripi[INVESTIGATOR_123124], which constitutes an important gap in the MRS literature.  However, a recent study evaluating the effect of a variety of psychotropic drugs, including aripi[INVESTIGATOR_4253], on 
Protocol  COL.AOM.2013.002 
 
Page 17 of 76 
Final Protocol: 29 July 2013 rat brain metabolites found increased NAA concentrations (a marker of neuronal viability and activity) in the frontal cortex and striatum24. Seminal work completed by [CONTACT_123256].[ADDRESS_138613] of aripi[INVESTIGATOR_123125], DT-MRI measures of white matter integrity, and concentration of neuronal metabolites in the brain.  In addition, we propose to examine the relationship between white matter integrity and neurocognitive and functional outcomes in relation to changes in brain structure and metabolic function.  7.2 ABILIFY® (ARIPI[INVESTIGATOR_123094]) Aripi[INVESTIGATOR_4253] (ABILIFY®) is a dopamine partial agonist discovered by [CONTACT_123257] (OPC) and co-developed by [CONTACT_414]-Myers Squibb and OPC.  Otsuka Pharmaceutical Company and H. Lundbeck A/S are jointly developi[INVESTIGATOR_123126].  Aripi[INVESTIGATOR_123127], maintenance of stability in adults with schizophrenia, treatment of acute manic epi[INVESTIGATOR_123128] I disorder in adults and pediatric patients, maintenance of efficacy in adults with bipolar I disorder, and as adjunctive treatment of major depressive disorder.  Aripi[INVESTIGATOR_123129] (EU), Australia, and a number of countries in Asia, Europe, and Latin America.  The aripi[INVESTIGATOR_123130]-release IM injection formulation is approved for agitation in schizophrenia and bipolar mania in the US and EU.  In addition, an oral solution formulation and orally disintegrating (dispersible) tablets have been approved and marketed in the US and EU.  The favorable side effect profile of oral aripi[INVESTIGATOR_4253], including its low incidence of extrapyramidal symptoms (EPS), low risk of prolactin elevation, decreased adrenergic and anticholinergic side effects, and minimal weight gain, makes it an excellent candidate for a long-acting once monthly formulation.  The aripi[INVESTIGATOR_123131]. A brief summary of nonclinical and clinical data is included below. 7.3 RELEVANT NONCLINICAL STUDIES The mechanism of action of aripi[INVESTIGATOR_123132].  It has been proposed that aripi[INVESTIGATOR_4253]’s effectiveness in schizophrenia is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism at serotonin 5-HT2 receptors.  Aripi[INVESTIGATOR_123133].AOM.2013.002 
 
Page 18 of 76 
Final Protocol: [ADDRESS_138614] negative symptoms in subjects with schizophrenia.  It seems likely that the favorable safety and tolerability profile of aripi[INVESTIGATOR_4253], including its low incidence of extrapyramidal symptoms (EPS), lack of prolactin elevation, decreased adrenergic and anticholinergic side effects, and decreased weight gain, is also mediated by [CONTACT_123258].  Please refer to the Investigator’s Brochure (IB)27 for information regarding nonclinical toxicity and pharmacokinetic (PK) studies conducted using aripi[INVESTIGATOR_123134]. 7.[ADDRESS_138615] support for the effectiveness, safety, and tolerability of aripi[INVESTIGATOR_123135].  Three Phase 3 studies established the efficacy of aripi[INVESTIGATOR_4253] 10, 15, 20, and 30 mg for the treatment of acute relapse of schizophrenia or schizoaffective disorder.  The two 4-week studies (31-97-[ZIP_CODE] and 31-97-202)29 each included 2 fixed doses of aripi[INVESTIGATOR_4253] (15 mg and 30 mg for 31-97-201 and 20 mg and 30 mg for 31-97-202), an active comparator, for comparison of safety profiles, and placebo.  Review of the data from these studies indicated that all of the doses of aripi[INVESTIGATOR_123136].  All aripi[INVESTIGATOR_123137] (PANSS) total score, PANSS positive score, and Clinical Global Impression-Severity (CGI-S) score.  As expected, the active comparators, haloperidol and risperidone, demonstrated effectiveness in the treatment of psychosis as measured by [CONTACT_123259].  The third double-blind, placebo-controlled, Phase 3 study (CN138001)30 was 6 weeks in duration and included aripi[INVESTIGATOR_123138] 10, 15, and 20 mg.  All doses of aripi[INVESTIGATOR_123139]. Three phase 3, double-blind, controlled studies were conducted to show the long-term efficacy of aripi[INVESTIGATOR_4253].  Study CN13804731,32 was a 26-week study designed to document the long-term efficacy of aripi[INVESTIGATOR_4253] 15 mg compared with placebo in stable schizophrenic subjects.  The primary efficacy variable was time to relapse from randomization, as measured by [CONTACT_123260] - Improvement (CGI-I) score ≥	
 5, PANSS scores for hostility or uncooperativeness ≥	
 5, or ≥	
 20% increase in PANSS total score.  The results indicated that 
Protocol  COL.AOM.2013.002 
 
Page 19 of 76 
Final Protocol: 29 July 2013 subjects treated with aripi[INVESTIGATOR_4253] 15 mg daily experienced a significantly longer time to relapse over the 26-week assessment period compared with those receiving placebo.  Two 52-week studies (Studies 31-98-217 and 31-98-304-01)33,34 of aripi[INVESTIGATOR_4253] 30 mg versus haloperidol 10 mg were conducted in acutely relapsing schizophrenic subjects with the intention of pooling the data for analysis.  On the primary efficacy measure (time to failure to maintain response in responders) no difference was seen between aripi[INVESTIGATOR_123140].  However, analysis of secondary efficacy measures showed that aripi[INVESTIGATOR_4253] [ADDRESS_138616]-rated and investigator-rated acceptability of aripi[INVESTIGATOR_123141]-label studies.  Subjects treated with open-label aripi[INVESTIGATOR_4253] 10 to 30 mg for 8 weeks indicated a general preference for aripi[INVESTIGATOR_123142](s) taken prior to entering the study (CN138087 and CN138100)35.  A separate open-label study (CN138152)36,37 compared aripi[INVESTIGATOR_4253] (10 to 30 mg daily) with SOC treatment (clinician-prescribed olanzapi[INVESTIGATOR_050], risperidone, or quetiapi[INVESTIGATOR_050]) in community-treated schizophrenic subjects for whom an alteration in antipsychotic medication was clinically warranted.  Aripi[INVESTIGATOR_123143]’s Assessment Questionnaire, which provides an overall assessment of efficacy and tolerability38. Aripi[INVESTIGATOR_123144], with no evidence of increased rates of somnolence, EPS-related side effects, clinically significant weight gain, hyperprolactinemia, or prolongation of corrected QT interval (QTc).  The recommended starting and target dose for aripi[INVESTIGATOR_123145] 10 mg or 15 mg/day administered on a once-a-day schedule without regard to meals.  Aripi[INVESTIGATOR_123146] a dose range of 10 mg to 30 mg/day; however, there is no evidence that doses higher than 15 mg per day are associated with increased efficacy.  Additional details of results of clinical studies with aripi[INVESTIGATOR_123147]’s Brochure.27 7.4.2 Agitation Studies with Injectable Aripi[INVESTIGATOR_123148]-release IM aripi[INVESTIGATOR_123149]-term (24-hour) placebo-controlled studies39.  Two studies in agitated inpatients with schizophrenia, schizoaffective disorder, or schizophreniform disorder showed that aripi[INVESTIGATOR_123150] 5.25, 9.75, and 15 mg/day was significantly more effective than placebo for controlling agitation, as measured by [CONTACT_123261] [ADDRESS_138617] IM injection.  A similar result was observed in agitated inpatients with bipolar disorder who received aripi[INVESTIGATOR_4253] 9.75 mg/day. 7.4.[ADDRESS_138618] IM formulation followed by [CONTACT_123262].  After a minimum 28-day washout, subjects who qualified based on no significant adverse events (AEs) 
Protocol  COL.AOM.2013.002 
 
Page 20 of 76 
Final Protocol: [ADDRESS_138619] AEs were mild (43%) to moderate (33%) in severity.  The most commonly reported treatment emergent AEs were headache (4 subjects, 19%) and anxiety (3 subjects, 14.3%).  All other AEs occurred in ≤ 2 subjects.  There were no discontinuations due to AEs and none of the AEs appeared to be dose-related.  There were two serious adverse events (SAEs), attempted suicide and exacerbation of schizophrenia, which were considered to be unrelated to study-drug. Otsuka Pharmaceutical Development & Commercialization, Inc. conducted a phase 1B study (Protocol 31-05-244) to assess the safety, tolerability, and PK of multiple doses of the aripi[INVESTIGATOR_123151].  The results showed that once-monthly administration of the 400-mg and 300-mg IM once monthly injections resulted in mean aripi[INVESTIGATOR_123152] 10-mg to 30-mg oral aripi[INVESTIGATOR_123153].  All 3 doses of aripi[INVESTIGATOR_123154] (200, 300, and 400 mg) demonstrated acceptable safety, tolerability, and potential effectiveness40. A phase 3 study (Protocol 31-07-246) was conducted to evaluate the efficacy and safety of aripi[INVESTIGATOR_123155] 12 weeks.  Aripi[INVESTIGATOR_123154] 400 or 300 mg administered as monthly injections was effective for the maintenance treatment of schizophrenia in adults as demonstrated by a statistically significant difference, compared with placebo, in the primary efficacy endpoint of time to impending relapse.  The percentage of subjects who met the criteria for impending relapse was significantly lower in the aripi[INVESTIGATOR_123156].  The maintenance of stability was also demonstrated by [CONTACT_123263][INVESTIGATOR_123157]-blind, placebo-controlled phase.  In addition, the Personal and Social Performance Scale (PSP) total score, cognitive function assessments, and IAQ score were supportive of the efficacy of aripi[INVESTIGATOR_123158].  Aripi[INVESTIGATOR_123159].  Most treatment-emergent adverse events (TEAEs) were either mild or moderate in severity.  The only TEAE reported by ≥ 5% of subjects receiving aripi[INVESTIGATOR_123160].  The increased rate of tremor over placebo treatment was consistent in studies with oral aripi[INVESTIGATOR_4253], as also reported in the aripi[INVESTIGATOR_123161].  Generally, AEs of tremor were mild in severity and occurred with a low frequency throughout the study.  No report of tremor was classified as a SAE or was associated with discontinuation of treatment.  There were no clinically relevant findings with regard to laboratory values, vital signs, weight, electrocardiogram (ECG) findings, EPS, suicidality, or injection site. 7.4.4 Known and Potential Risks and Benefits As of 10 Jun 2010, 15,088 adult patients were treated with aripi[INVESTIGATOR_123162] 2, 3, and 4 studies (representing 8577 patient-exposure years).  Of these, 3901 (25.9%) patients were treated with aripi[INVESTIGATOR_92563] 180 days or longer; 2259 (15.0%) patients received 
Protocol  COL.AOM.2013.002 
 
Page 21 of 76 
Final Protocol: [ADDRESS_138620] 360 days, with 933 (6.2%) patients continuing aripi[INVESTIGATOR_123163] 720 days. Across the short-term, double-blind, placebo-controlled studies conducted in schizophrenic subjects, the AE profile of oral aripi[INVESTIGATOR_123164].  There was little difference in the incidence of discontinuation due to AEs between aripi[INVESTIGATOR_4253]-treated (7%) and placebo-treated (9%) subjects.  Akathesia was the only commonly observed AE that occurred in ≥ 5% of aripi[INVESTIGATOR_4253]-treated subjects and at an incidence more than twice that of placebo (8% vs 4%, respectively).  Aripi[INVESTIGATOR_123165]-tolerated in the long-term studies.  Changes in body weight, fasting glucose, lipid profile, and serum prolactin levels were similar between aripi[INVESTIGATOR_4253]- and placebo-treated subjects.  No clinically relevant changes in QTc were observed in either group32.  In the pooled analysis of the two 52-week studies comparing aripi[INVESTIGATOR_123166], the incidence of EPS-related AEs was significantly higher for haloperidol (58%) compared with aripi[INVESTIGATOR_4253] (27%).  In the one 52-week study in which prolactin levels were measured, significantly fewer aripi[INVESTIGATOR_4253]-treated subjects (3.4%) experienced prolactin elevations above the upper limit of normal compared with the haloperidol group (61%)34.  The comparative safety profile of oral aripi[INVESTIGATOR_123167].  Additionally, aripi[INVESTIGATOR_123168] a more favorable safety profile than haloperidol in the 26-week active-controlled study in acute bipolar mania.  The safety profile was consistent with that observed in haloperidol-controlled schizophrenia studies, as evidenced by a lower incidence of AE discontinuation, EPS-related AEs, and prolactin elevation41. Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypi[INVESTIGATOR_30265].  There have been few reports of hyperglycemia in subjects treated with aripi[INVESTIGATOR_4253].  Although fewer subjects have been treated with aripi[INVESTIGATOR_4253], it is not known if this more limited experience is the sole reason for the paucity of such reports.  Assessment of the relationship between atypi[INVESTIGATOR_123169].  Given these confounders, the relationship between atypi[INVESTIGATOR_123170]-related AEs is not completely understood.  However, epi[INVESTIGATOR_123171]-emergent hyperglycemia-related AEs in subjects treated with the atypi[INVESTIGATOR_123172].  Because aripi[INVESTIGATOR_123173], it is not known if aripi[INVESTIGATOR_123174].  Precise risk estimates for hyperglycemia-related AEs in subjects treated with atypi[INVESTIGATOR_123175]. Elderly patients with dementia-related psychosis treated with atypi[INVESTIGATOR_123176], including aripi[INVESTIGATOR_4253], are at an increased risk of death compared with placebo.  Over the course of three 10-week, placebo-controlled studies of aripi[INVESTIGATOR_123177]’s disease, the rate of death in aripi[INVESTIGATOR_4253]-treated subjects was 3.5%, compared with a rate of 1.7% in the placebo group during or within 30 days after termination 
Protocol  COL.AOM.2013.002 
 
Page 22 of 76 
Final Protocol: [ADDRESS_138621] of the deaths were either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  Overall, 1.3% of aripi[INVESTIGATOR_4253]-treated subjects reported cerebrovascular AEs (e.g., stroke, transient ischemic attack) compared with 0.6% of placebo-treated subjects in these studies.  This difference was not statistically significant.  However, in one of these studies, a fixed-dose study, there was a significant dose-response relationship for cerebrovascular AEs in patients treated with aripi[INVESTIGATOR_4253].  Aripi[INVESTIGATOR_123178]-related psychosis.  In clinical studies and postmarketing experience, accidental or intentional acute overdose of aripi[INVESTIGATOR_123179] 1260 mg with no fatalities.  The potentially medically important signs and symptoms observed included lethargy, increased blood pressure, somnolence, tachycardia, and vomiting.  In addition, reports of accidental overdose with aripi[INVESTIGATOR_123180] (up to 195 mg) in children were received with no fatalities.  The potentially medically serious signs and symptoms reported included somnolence and transient loss of consciousness.  In the patients who were evaluated in hospi[INVESTIGATOR_69225], there were no reported observations indicating clinically important adverse changes in vital signs, laboratory assessments, or ECGs.  Additional information can be obtained from the ABILIFY [LOCATION_002] (US) package insert. 7.[ADDRESS_138622] recovery.  Improved adherence to psychotropic treatment may therefore lead to greater symptomatic improvements in this patient population. By [CONTACT_123264], once monthly aripi[INVESTIGATOR_123181].    It is hypothesized that improved treatment compliance will lead to fewer white matter changes in the brain.  Fewer white matter changes will be demonstrated via neuroimaging as increased FA and BPF values in the prefrontal region, and an increase in metabolites in a voxel centered on the anterior cingulate cortex (ACC) as seen with MRS.  Therefore, the aim of this study is to examine the structural and metabolic effects of aripi[INVESTIGATOR_123182]. 
Protocol  COL.AOM.2013.002 
 
Page 23 of 76 
Final Protocol: 29 July 2013 8 STUDY OBJECTIVES 8.1 PRIMARY OBJECTIVE(S) The primary objective of the study is: • To determine if there are differences from baseline in prefrontal white matter FA after 6 and 12 months of treatment with once monthly aripi[INVESTIGATOR_123183].  8.2 SECONDARY OBJECTIVE(S) The secondary objectives of the study are: • To determine if there are differences from baseline in water BPF in prefrontal white matter after 6 and 12 months of treatment with once monthly aripi[INVESTIGATOR_123183]. • To determine if proton metabolites, specifically GABA, glutamine, and glutamate, are altered after 6 and 12 months of treatment with once monthly aripi[INVESTIGATOR_123183], compared with baseline. • To determine if there are differences from baseline in regional white and gray matter volume after 6 and 12 months of treatment with once monthly aripi[INVESTIGATOR_123183]. • To determine the effect on clinical and behavioral assessments of schizophrenia after 12 months with aripi[INVESTIGATOR_123100], compared with baseline. 8.3 EXPLORATORY OBJECTIVE(S) The exploratory objective of the study is: • To determine if there is a demonstrated association between clinical and neurocognitive variables and FA, BPF, and metabolite concentrations in subjects with schizophrenia receiving SOC oral antipsychotic medications or once monthly aripi[INVESTIGATOR_4253]. 
Protocol  COL.AOM.2013.002 
 
Page 24 of 76 
Final Protocol: [ADDRESS_138623] of care (SOC) oral antipsychotic therapy.  A total of 80 subjects are planned to be enrolled in the study in a 3:1 subjects with schizophrenia:control ratio, to allow for 60 completed subjects:  45 subjects with Diagnostic and Statistical Manual of Mental Disease – Fourth Edition, Text Revised (DSM-IV-TR) schizophrenia, and 15 age-, gender-, and education-matched healthy control subjects.  Prospective subjects will undergo a thorough psychiatric and clinical screening phase, including a physical and neurological examination, 12-lead electrocardiogram (ECG), and clinical laboratory testing.  All subjects with schizophrenia will be evaluated using appropriate rating scales for psychosis, negative symptoms, depression, suicidality, and psychosocial functioning.   After screening, subjects with schizophrenia will be randomized in a 2:1 aripi[INVESTIGATOR_123104]:oral SOC antipsychotics ratio to the aripi[INVESTIGATOR_123184].  Subjects with schizophrenia who are randomized to the aripi[INVESTIGATOR_123185] a medication washout and a conversion (Phase A) to oral aripi[INVESTIGATOR_123107].  In addition, any subject who is still taking prohibited medication will enter Phase A for the appropriate washout.  All subjects with schizophrenia will proceed to Phase B (Stabilization) directly after screening, or after Phase A if conversion to oral aripi[INVESTIGATOR_123108].  For those subjects in the oral SOC antipsychotic arm, once stable on SOC oral antipsychotic medications for 2 consecutive visits, the subjects will proceed into Phase C (Treatment).  Control subjects will enter Phase C directly after screening.  All subjects with schizophrenia will undergo neuropsychological testing, clinical ratings, and multimodal MRI acquisition.  The MRI scanning protocol includes high-resolution MR, diffusion tensor (DT)-MRI, water-BPF, and magnetic resonance spectroscopy (MRS).  Neuropsychological testing, clinical ratings, and multimodal MRI acquisitions will be performed after 6 and 12 months of treatment.  The subjects will be assessed at regularly scheduled visits according to the schedules of assessments (Table 4 through Table 7).  Six and 12-month MRI indices in subjects receiving once monthly aripi[INVESTIGATOR_123109], the data from subjects with schizophrenia who are receiving SOC oral antipsychotic medications, and the healthy control subjects.   Clinical assessments including suicidality, mood, extrapyramidal side effects (EPS), and adverse drug effects are:  Abnormal Involuntary Movement Scale (AIMS), Barnes Akathesia Rating Scale (BARS), Clinical and Global Impression – Improvement (CGI-I), Clinical and Global Impression – Severity (CGI-S), Clinical and Global Impression -  Severity of Suicidality (CGI-SS), Columbia Suicide Severity Rating Scale (C-SSRS), Hamilton Anxiety Scale (HAM-A), Hamilton Depression Rating Scale (HAM-D), Medication Adherence Questionnaire (MAQ), Monitoring of Side Effects Scale (MOSES), Positive and Negative Symptom Scale (PANSS), Profile of Mood States (POMS), and Simpson Angus Scale (SAS). 
Protocol  COL.AOM.2013.002 
 
Page 25 of 76 
Final Protocol: [ADDRESS_138624] been related to suicidal ideation and suicide attempts.  Expression of suicidal ideation or behaviors will be followed up verbally or, depending on the severity, through further clinical action. Neuropsychological testing will include:  The CogState tests which include Simple Reaction Time, Choice Reaction Time, One-back Working memory, Two-back Working Memory, and Set Shifting. Other neuropsychological tests will be the TrailMaking Test, Tower of London, Continuous Performance Test (CPT) and the Wisconsin Card Sorting Test (WCST). Functional assessments will include:  Functional Assessment Test (FAST), Quality of Life Scale (QOLS), Social and Occupational Functioning Assessment Scale (SOFAS), and Life Functioning Questionnaire (LFQ). Healthy control subjects will not receive any study drug; however these subjects will undergo MRI imaging for comparison with the subjects with schizophrenia. Compliance with SOC antipsychotic drugs will be managed using medication possession ratio (MPR) for prescription refills, and the self-reported MAQ. The trial schematic is provided in Figure 1. 
Protocol  COL.AOM.2013.002 
 
Page 26 of 76 
Final Protocol: 29 July 2013                     Figure 1 Study Schematic  
Screening 
Randomization 
Phase A  (Conversion) 
Phase B (Stabilization) 
Phase C  (Treatment) 
Total [ADDRESS_138625] meet stability criteria for two consecutive visits. 
4 to 6 weeks 
4 to 12 weeks 
Subjects who meet stability criteria.  Treatment with aripi[INVESTIGATOR_123186]. 
12 months 
Total 20 healthy  control subjects 
These subjects do not receive  any study drug.  All other Phase C assessments will be completed. 
Protocol  COL.AOM.2013.002 
 
Page 27 of 76 
Final Protocol: [ADDRESS_138626] full responsibility for all issues pertaining to assent and informed consent.  The Screening Visit will occur on Days -7 to -2.  Eligibility for the study will be determined via the following: • Review of the inclusion and exclusion criteria • Complete medical history and demographic data • Assessment of current antipsychotic treatment and the stability of the current medication regimen • Structured Clinical Interview for DSM-IV Patient Version (SCID-P) to determine Axis I disorders including substance use/dependence disorders • Serum beta human chorionic gonadatropin (βhCG) pregnancy test for all women of childbearing potential to ensure that individuals are appropriate for imaging. Subjects who are found to be pregnant or have metal implants, pacemakers, prosthetic devices, or other situations or conditions that preclude the ability to participate in the imaging studies will not be entered into the study. • Physical examination, including height and weight, and vital signs (body temperature, supi[INVESTIGATOR_123187], and heart rate) measurements • Baseline clinical laboratory tests (See Section [IP_ADDRESS].[ADDRESS_138627]) • Serum prolactin concentration • 12-lead electrocardiogram (ECG) • Urine drugs of abuse screen • Blood alcohol content 
Protocol  COL.AOM.2013.002 
 
Page 28 of 76 
Final Protocol: [ADDRESS_138628] dose of study drug will be recorded.  Concomitant medications including details (e.g., drug name, dose, and frequency) of all current antipsychotic medication(s) will be recorded.   Washout from prohibited concomitant medications will begin, if applicable. 9.1.[ADDRESS_138629] visit for Phase A; all other subjects will have their baseline visit for Phase B either at the screening visit or on Day 1 of Phase B. At the Baseline Visits, the inclusion and exclusion criteria, current antipsychotic therapy, and concomitant medication use will be reviewed and recorded. Vital signs and body weight will be measured and body mass index (BMI) will be calculated. The following core measures will be assessed: 1. Clinical Outcomes  a. Positive and Negative Syndrome Scale (PANSS) b. Medication Adherence Questionnaire (MAQ) c. Clinical and Global Impression - Severity (CGI-S) d. Clinical and Global Impression - Severity of Suicidality (CGI-SS) e. Clinical and Global Impression – Improvement (CGI-I) f. Columbia Suicide Severity Rating Scale (C-SSRS) g. DSM-IV-TR Global Assessment of Functioning (GAF) 2. Mood  a. Profile of Mood States (POMS) b. Hamilton Anxiety Scale (HAM-A) c. Hamilton Depression Rating Scale (HAM-D) 3. Extrapyramidal Side Effects a. Simpson Angus Scale (SAS) b. Abnormal Involuntary Movement Scale (AIMS) c. Barnes Akathesia Rating Scale (BARS) 4. Adverse Drug Effects 
Protocol  COL.AOM.2013.002 
 
Page 29 of 76 
Final Protocol: 29 July 2013 a. Monitoring of Side Effects Scale (MOSES) Subjects will be given prescriptions for their oral SOC antipsychotic medications. At the end of the baseline visit, for subjects who were randomized to aripi[INVESTIGATOR_123188], cross-titration will begin (Phase A).  In addition, any subjects who must undergo a washout from prohibited medications (see Section 9.4.5Error! Reference source not found.) will enter Phase A to complete the washout.  Subjects with schizophrenia who are randomized to the SOC oral antipsychotic arm who do not need to undergo washout from prohibited medications will move directly into Phase B.  9.1.3 Randomization All subjects with schizophrenia will be randomized to the aripi[INVESTIGATOR_123189] a 2:[ADDRESS_138630]-to-follow up, discontinue the study, or fail to meet conversion or stability criteria. This will be an open-label study.  All clinical personnel, investigators, and subjects will be knowledgeable regarding the study treatment.  [IP_ADDRESS] Overall Treatment ● Aripi[INVESTIGATOR_123190]’s judgment and in accordance with product labeling, administered via gluteal IM injection once monthly.   ● SOC oral antipsychotic medications (PO) will be prescribed by [CONTACT_123265]’s judgment and in accordance with product labeling and include but are not limited to aripi[INVESTIGATOR_4253] (Abilify®), risperidone (Risperdal®), lurasidone HCl (Latuda®), quetiapi[INVESTIGATOR_123111] (Seroquel®), olanzapi[INVESTIGATOR_050] (Zyprexa®), and ziprasidone HCl (Geodon®). [IP_ADDRESS] Phase A – Conversion During Phase A, all subjects randomized to aripi[INVESTIGATOR_123191]-titration to receive oral aripi[INVESTIGATOR_123107], [ADDRESS_138631] requiring washout from prohibited medications will enter Phase A and prohibited medications will be withdrawn on a schedule based on the investigator’s judgment. 
Protocol  COL.AOM.2013.002 
 
Page 30 of 76 
Final Protocol: 29 July 2013 [IP_ADDRESS] Phase B – Stabilization During Phase B, all enrolled subjects will be receiving SOC oral antipsychotic medication until stability criteria are met for two consecutive visits.  All oral antipsychotic medications will be prescribed using doses consistent with their respective product labeling. [IP_ADDRESS] Phase C – Treatment During Phase C: ● A total of 30 to 40 subjects with schizophrenia will receive aripi[INVESTIGATOR_123104], at a starting dose of 400 mg IM or an approved dose based on the investigator’s judgment and in accordance with product labeling.  In addition, these subjects will continue to receive oral aripi[INVESTIGATOR_123192] (10 to 20 mg PO, daily) given prior to Phase C for 14 days. ● A total of [ADDRESS_138632] (DSMB) will oversee the current study.  Monitoring will include completion of a site initiation visit, interim monitoring visits, submission of monitoring reports, oversight of regulatory paperwork, and oversight of IRE/SAE review of monthly enrollment logs. The scanning methods to be employed in this study are superior to those utilized in previous investigations as the current protocol will use higher magnetic resonance imaging field strength to collect data and more advanced analytical strategies for image analysis.  As such, the effect sizes are expected to be larger and, because multimodal imaging protocols will be implemented, it is expected that this study will produce a number of significant, complimentary clinical findings. 
Protocol  COL.AOM.2013.002 
 
Page 31 of 76 
Final Protocol: 29 July 2013 This is an open-label study.  Randomization is used in the study to mitigate the potential for bias in allocation of study drug. 9.3 SELECTION OF STUDY POPULATION Approximately 80 subjects are planned for enrollment into the study at the Brain Institute.  There will be up to 60 subjects with a diagnosis of DSM-IV-TR schizophrenia and 15 to 20 age-, gender-, and education-matched healthy control subjects enrolled in a 3:1 subjects with schizophrenia:control subjects ratio.  This, accounting for drop-outs, will allow for 60 completed subjects:  45 subjects with schizophrenia and 15 healthy control subjects.  Subjects who do not meet all of the inclusion criteria or who meet any of the exclusion criteria will not be eligible to receive study drug.  After screening, subjects with schizophrenia will be randomized in a 2:1 aripi[INVESTIGATOR_123104]:SOC oral antipsychotics ratio. The enrollment estimates for the study are provided in Table 1: Table 1: Estimated Enrollment - Subjects Completed Per Year Subject type Year 1 Year 2 Total n Healthy controls 7 8 15 SCZ subjects treated with depot aripi[INVESTIGATOR_4253] 15 15 30 SCZ subjects treated with SOC oral antipsychotics 7 8 15 Total 29 31 60 SCZ = schizophrenia, SOC = standard of care  9.3.1 Inclusion Criteria [IP_ADDRESS] Inclusion Criteria for All Subjects 1 Are able to provide written informed consent. 2 Are male and female subjects 18 to 35 years of age, inclusive, at time of informed consent. [IP_ADDRESS] Inclusion Criteria for Subjects with Schizophrenia 1. Have a current diagnosis of schizophrenia as defined by [CONTACT_2681]-IV-TR criteria and a history of the illness for at least [ADDRESS_138633] two prior psychotic epi[INVESTIGATOR_123193] a qualified and reliable health care provider. 2. Require, in the investigator's judgment, chronic treatment with an antipsychotic medication. 3. Are able to understand the nature of the study and follow protocol requirements, including the prescribed dosage regimens, tablet ingestion, IM depot injection, and discontinuation of prohibited concomitant medications, read and understand the written 
Protocol  COL.AOM.2013.002 
 
Page 32 of 76 
Final Protocol: [ADDRESS_138634]-reported outcomes measures, and be reliably rated on assessment scales. 4. Are male and female subjects who are surgically sterile (i.e., have undergone orchiectomy or hysterectomy, respectively; female subjects who have been postmenopausal for at least 12 consecutive months; or male and female subjects who agree to remain abstinent or to practice double-barrier forms of birth control from trial screening through 30 days (for females) and 90 days (for males) from the last dose of IMP for SOC oral antipsychotics and [ADDRESS_138635] be used:  vasectomy, tubal ligation, vaginal diaphragm, intrauterine device, birth control pi[INVESTIGATOR_4382], birth control implant, birth control depot injections, condom, or sponge with spermicide.  9.3.2 Exclusion Criteria [IP_ADDRESS] Exclusion Criteria All Subjects 1. Presence of any metal implants, pacemakers, unremovable prosthetic device, or other device or situation that may preclude imaging 2. History of a head injury with loss of consciousness > [ADDRESS_138636] to undue risk or interfere with study assessments. [IP_ADDRESS] Exclusion Criteria for Subjects with Schizophrenia  1. Has a current DSM-IV-TR diagnosis other than schizophrenia, including schizophreniform disorder, schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic or other cognitive disorders.  Also excluded are subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder. 2. Is considered resistant/refractory to antipsychotic treatment by [CONTACT_969] (failed two prior antipsychotic medication trials) or response only to clozapi[INVESTIGATOR_050]. 3. Has a significant risk of violent behavior or a significant risk of committing suicide based on history or investigator's discretion. 4. Has met DSM-IV-TR criteria for any significant substance use disorder within 3 months prior to screening, excluding caffeine, nicotine, or marijuana. 5. Is known to be allergic, intolerant, or unresponsive to prior treatment with aripi[INVESTIGATOR_92622], or hypersensitivity to antipsychotic agents, including aripi[INVESTIGATOR_4253]. 
Protocol  COL.AOM.2013.002 
 
Page 33 of 76 
Final Protocol: 29 July 2013 6. Has a history of neuroleptic malignant syndrome or clinically significant tardive dyskinesia at screening per the investigator’s discretion. 7. Has a history of seizures or any other medical condition that would expose the subject to undue risk or interfere with study assessments. 8. Is involuntarily incarcerated. 9. Has undergone electroconvulsive therapy in the [ADDRESS_138637] results, vital signs, or ECG results. 12. Requires more than one benzodiazepi[INVESTIGATOR_123194] (e.g., lorazepam and oxazepam). 13. Fails to washout from prohibited concomitant medications, including the use of or CYP3A4 inducers, a second antipsychotic, antidepressants (including monoamine oxidase inhibitors), and mood stabilizers. 9.3.3 Removal of Subjects From Therapy or Assessment [IP_ADDRESS] Entire Study or Treatment Arm(s) If the investigator terminates or suspends the study for safety or unanticipated other reasons, prompt notification will be given to OAPI, IRBs, and regulatory authorities in accordance with regulatory requirements. [IP_ADDRESS] Individual Center The investigator will notify OAPI [INVESTIGATOR_123195]. [IP_ADDRESS] Individual Subject If a subject discontinues from the study prematurely, the reason must be fully evaluated and recorded appropriately in source documents and the CRF.  If the subject is being withdrawn because of an AE, that AE should be indicated as the reason for withdrawal. An increase in suicidal ideation or homicidal ideation will result in withdrawal from the study, based on the investigators discretion. All subjects have the right to withdraw at any point during treatment without prejudice.  The investigator can discontinue a subject’s participation in the study at any time if medically necessary.  In addition, subjects meeting the following criteria must be withdrawn from the study: 
Protocol  COL.AOM.2013.002 
 
Page 34 of 76 
Final Protocol: [ADDRESS_138638]’s permanent withdrawal from the study; 2. treatment with a prohibited concomitant medication other than the use of appropriate medications for the treatment of adverse events under direction of the investigator; 3. subject noncompliance, defined as refusal or inability to adhere to the study schedule or procedures per the investigator’s discretion; 4. at the request of the subject, investigator, OAPI [INVESTIGATOR_1461], or regulatory authority 5. subject becomes pregnant; or 6. subject is lost to follow-up. The Investigator will notify OAPI [INVESTIGATOR_123196] a subject is withdrawn. 9.[ADDRESS_138639] labeling. The following treatments will be administered to subjects in this study: • Aripi[INVESTIGATOR_4253] (IM), 300 or 400 mg administered via gluteal injection, once monthly. • SOC oral antipsychotic medications (PO) including but not limited to: o Aripi[INVESTIGATOR_4253] (Abilify®), 10 mg to 30 mg, daily o Risperidone (Risperdal®), 2 to 8 mg daily o lurasidone HCl (Latuda®), 40 to 160 mg daily o quietapi[INVESTIGATOR_123111] (Seroquel®), 300 to 800 mg daily o olanzapi[INVESTIGATOR_050] (Zyprexa®) 10 to 30 mg daily o ziprasidone HCl (Geodon®) 40 to 160 mg daily [IP_ADDRESS] Dosage Adjustments for Missed Doses of Aripi[INVESTIGATOR_123197]: 
Protocol  COL.AOM.2013.002 
 
Page 35 of 76 
Final Protocol: 29 July 2013 ● If > 4 weeks and < [ADDRESS_138640] injection, administer the injection as soon as possible. ● If > [ADDRESS_138641] injection, restart concomitant oral aripi[INVESTIGATOR_92563] 14 days with the next administered injection. If the fourth or subsequent doses are missed: ● If > 4 weeks and < [ADDRESS_138642] injection, administer the injection as soon as possible. ● If > [ADDRESS_138643](s) Study drugs will not be stored at the clinical site.  If, on occasion, study drug is stored at the site for any reason, all drug will be securely locked in a cabinet or enclosure according to the storage instructions on the product labeling.  Access will be limited to the investigators and their designees.  Neither investigators nor any designees may provide study drugs to any subject not participating in this protocol. 9.4.3 Method of Assigning Subjects to Treatment Groups A total of 80 subjects are planned to be enrolled in the study in a 3:1 subjects with schizophrenia:control ratio, to allow for 60 completed subjects:  45 subjects with schizophrenia, and 15 age-, gender-, and education-matched healthy control subjects.  9.4.4 Blinding The study will not be blinded. 9.4.5 Prohibited Medication Medications that are prohibited or restricted prior to screening and/or during the study are listed in Table 2. 
Protocol  COL.AOM.2013.002 
 
Page 36 of 76 
Final Protocol: 29 July 2013  Table 2: Prohibited and Restricted Medications Medication Prohibition or Restriction Antipsychotics No more than one SOC antipsychotic allowed Antidepressants including MAOIs Not allowed Benzodiazapi[INVESTIGATOR_123198].  Mood stabilizers Not allowed Non-benzodiazapi[INVESTIGATOR_123199] ≤ 4 mg/day benztropi[INVESTIGATOR_92652]; not within 12 hours of any rating scales. Propanolol for akathisia or tremor Maximum 60 mg/day; not within 8 hours of any rating scales.  Subjects receiving propanolol for heart disease may remain on stable, pre-study doses, as needed as long as the dose does not exceed 60 mg/day. Varenicline Not allowed Nutritional supplements and non-prescription herbal preparations with CNS effects (e.g., St. John’s Wort, omega-3 fatty acids, kava extracts, GABA supplements) Not allowed CYP3A4 or CYP2D6 inhibitors or CYP3A4 inducers CYP3A4 or CYP2D6 inhibitors are allowed, however, the investigator may adjust the dose of the study drug per the prescribing instructions. CYP3A4 inducers are not allowed Hydroxyzine and diphenhydramine  Not allowed for the treatment of agitation, anxiety, insomnia, or EPS; Allowed for the treatment of allergy. AE – adverse event, CNS = central nervous system, CYP = cytochrome P450, EPS = extrapyramidal side effects, GABA = gamma aminobutyric acid, IM = intramuscular, MAOI = monoamine oxidase inhibitor a:  Zolpi[INVESTIGATOR_6730] 5 to 10 mg/day, zolpi[INVESTIGATOR_123200]-release 12.5 mg/day, zaleplon 5 to 10 mg/day, zopi[INVESTIGATOR_11123] 3.75 to 7.5 mg/day, or eszopi[INVESTIGATOR_11123] 1 to 3 mg/day is permitted, but not in addition to a benzodiazepi[INVESTIGATOR_123201].  9.4.6 Treatment Compliance Compliance with SOC drug will be managed using the MPR (Section Error! Reference source not found.) for prescription refills and the MAQ (Section Error! Reference source not found.). 9.4.7 Accountability Study drug will not be prescribed or administered until the following documentation has been provided by [CONTACT_123266]: ● A signed and dated confidentiality agreement 
Protocol  COL.AOM.2013.002 
 
Page 37 of 76 
Final Protocol: 29 July 2013 ● A copy of the final signed and dated protocol signature [CONTACT_3264] ● Written proof of approval of the protocol, the ICFs, and any other information provided to the subjects by [CONTACT_123267] ● A copy of the IRB-approved ICF and any other documentation provided to the subjects to be used in this study ● The IRB membership list and statutes or Health and Human Services Assurance number ● A copy of the certification and a table of the normal laboratory ranges for the reference laboratory conducting the clinical laboratory tests required by [CONTACT_3181] ● An investigator-signed and dated Food and Drug Administration (FDA) Form FDA 1572, where applicable ● Financial Disclosure form(s) for the investigator and all subinvestigators listed on Form FDA 1572, where applicable ● A signed and dated curriculum vitae (CV) of the investigator including a copy of the investigator’s current medical license or medical registration number on the CV ● A signed and dated clinical studies agreement The investigator and the study staff will be responsible for the accountability of all study drugs (dispensing, inventory, and record keepi[INVESTIGATOR_007]) following the, and adherence to, Good Clinical Practice (GCP) guidelines as well as local or regional requirements. Under no circumstances will the investigator allow the study drugs to be used other than as directed by [CONTACT_3181].  Study drugs will not be administered or prescribed to any individual who is not enrolled in the study.   The investigator, or designee, must maintain an inventory record of trial drugs (including study drug, active control, or placebo) received, dispensed, administered and returned. The study drugs and inventory records must be made available, upon request, for inspection by a designated representative of OAPI [INVESTIGATOR_1660] a representative of a health authority (e.g., FDA).  As applicable, all unused study drugs are to be returned to the investigator by [CONTACT_423]. 9.5 STUDY ASSESSMENTS 9.5.1 Assessments [IP_ADDRESS] Demographics Subject demographic information will be collected at the Screening Visit.  Demographic information includes date of birth (or age), sex, race or ethnicity. 
Protocol  COL.AOM.2013.002 
 
Page 38 of 76 
Final Protocol: 29 July 2013 [IP_ADDRESS] Screening Assessments MEDICAL HISTORY Medical and surgical history and current medical conditions will be recorded at the Screening Visit.  All relevant medical and surgical history within [ADDRESS_138644]’s psychiatric history will be performed including all antipsychotic medications used within the 6 months prior to screening.  Confirmation of the diagnosis of schizophrenia, as defined by [CONTACT_2681]-IV-TR criteria. [IP_ADDRESS] Safety Assessments Safety will be assessed by [CONTACT_60235] (AE) reporting, clinical laboratory tests (hematology and fasting clinical chemistry), urinalysis, 12-lead ECG, vital signs, and physical examination.  In addition, body weight, BMI, and serum prolactin concentrations will be monitored. The MOSES will be utilized to assess for side effects, and the following scales will be used to assess for EPS:  AIMS, SAS, and BARS. For subjects receiving an injection, the investigator, or qualified designee, will assess the injection site for localized pain, redness, swelling, and induration. [IP_ADDRESS].[ADDRESS_138645].  Samples will be obtained at the visits designated in Table 4 through Table 6, and as far as possible, samples should be drawn at the same time of day at each visit.  Additional samples may be collected for further evaluation of safety as warranted by [CONTACT_093]’s discretion.  Subjects should be fasting for a minimum of 10 hours prior to blood draws for assessment of safety, including screening.  If non-fasting blood samples are obtained initially for determining eligibility for the study, a fasting blood sample should be drawn prior to enrollment.  The clinical laboratory tests performed during the study are provided in Table 3. 
Protocol  COL.AOM.2013.002 
 
Page 39 of 76 
Final Protocol: 29 July 2013 Table 3. Safety Clinical Laboratory Tests Hematology:  White Blood Cell (WBC) count with differential  Red Blood Cell (RBC) count  Hematocrit  Hemoglobin Mean Corpuscular Volume (MCV) Mean Corpuscular Hemoglobin Concentration (MCHC)  Serum Chemistry:  Alanine Transaminase (ALT) Alkaline Phosphatase (ALP) Aspartate Transaminase (AST) Bilirubin, Total Blood Urea Nitrogen (BUN)  Calcium Cholesterol Creatinine  Gamma Glutamyl Transferase (GGT) Glucose Lactic Dehydrogenase (LDH) Potassium Protein, Total Sodium  Triglycerides  Urinalysis: Color Appearance pH Specific gravity Microscopic Analysis of RBC/WBC (per high powered field)] Additional Tests:  Urine β-hCGa for women of child-bearing potential   Serum prolactin  β-hCG = beta human chorionic gonadatropin a:  Serum β-hCG will be performed if the subject or investigator suspects that the subject may be pregnant.  [IP_ADDRESS].2 Physical Examination Physical examinations (comprehensive or symptom directed) will be performed as designated on the Schedules of Assessments (Table 4 through Table 6).  A comprehensive physical examination will include evaluations of the head, eyes, ears, nose, throat, neck, chest (including heart and lungs), abdomen, limbs, skin, and a complete neurological examination.  A urogenital examination will only be required in the presence of clinical symptoms related to this region.  Documentation of the physical examination will be included in the source documentation.  Significant findings at the Screening Visit will be recorded on the CRF.  Changes from screening physical examination findings that meet the definition of an AE will be recorded on the Adverse Events CRF. ECG Assessments A 12-lead ECG will be performed in triplicate while the subject is in a supi[INVESTIGATOR_123202] [ADDRESS_138646] An adverse event (AE) is any untoward medical occurrence in a subject or clinical investigation subject administered an investigational product.  An AE does not necessarily have a causal relationship with the study product.  For this study, the study drugs are aripi[INVESTIGATOR_123203]. The criteria for identifying AEs are: 
Protocol  COL.AOM.2013.002 
 
Page 40 of 76 
Final Protocol: 29 July 2013 ● Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product ● Any new disease or exacerbation of an existing disease ● Any deterioration in nonprotocol-required measurements of a laboratory value or other clinical test (e.g., ECG or x-ray) that results in symptoms, a change in treatment, or discontinuation of study drug ● Recurrence of an intermittent medical condition (e.g., headache) not present pretreatment (Baseline) ● An abnormal laboratory test result should be considered an AE if the identified laboratory abnormality leads to any type of intervention, whether prescribed in the protocol or not. A laboratory result should be considered by [CONTACT_76702]: ● Results in the withdrawal of study drug ● Results in withholding of study drug pending some investigational outcome ● Results in an intervention, based on medical evaluation (e.g., potassium supplement for hypokalemia) ● Results in any out of range laboratory value that in the investigator’s judgment fulfills the definitions of an AE with regard to the subject’s medical profile All AEs observed during the study will be reported on the CRF.  All AEs, regardless of relationship to study drug or procedure, should be collected beginning from the time the subject signs the study ICF through the last visit.  Serious AEs will be collected for [ADDRESS_138647] dose. Abnormal laboratory values should not be listed as separate AEs if they are considered to be part of the clinical syndrome that is being reported as an AE.  Any laboratory abnormality considered to constitute an AE should be reported as an AE on the CRF. It is the responsibility of the investigator to review all laboratory findings in all subjects and determine if they constitute an AE.  Medical and scientific judgment should be exercised in deciding whether an isolated laboratory abnormality should be classified as an AE. It is the responsibility of the investigator to review the results of the C-SSRS and CGI-SS in all subjects and determine if any result constitutes an AE.  Medical and scientific judgment should be exercised in deciding whether an isolated suicidality rating scale response should be classified as an AE (see Other Safety Assessments [Section [IP_ADDRESS]] for a description of the C-SSRS and CGI-SS). 
Protocol  COL.AOM.2013.002 
 
Page 41 of 76 
Final Protocol: [ADDRESS_138648] they might be pregnant (e.g., missed or late menstrual cycle). Assessing Severity of Adverse Events Standard Text AEs will be graded on a 3-point scale (mild, moderate, severe) and reported in the detail indicated on the CRF.  The definitions are as follows: Mild Discomfort noticed, but no disruption of normal daily activity Moderate Discomfort sufficient to reduce or affect normal daily activity Severe Incapacitating, with inability to work or to perform normal daily activity The criteria for assessing severity are different than those used for seriousness (see Serious Adverse Events and Other Events of Interest [Section [IP_ADDRESS]] for the definition of an SAE). The causal relationship of the study drug to an AE will be assessed as related or unrelated, as follows: Related: Definite: There is a reasonable causal relationship between the study drug and the AE, when the event responds to withdrawal of the study drug (dechallenge), and recurs with rechallenge by [CONTACT_123268]. Probable: There is a reasonable causal relationship between the study drug and the AE.  The event responds to dechallenge.  Rechallenge is not required. Possible: There is a reasonable causal relationship between the study drug and the AE.   Dechallenge is lacking or unclear.  Unrelated: Not Likely: There is a temporal relationship to study drug administration, but there is not a reasonable causal relationship between the study drug and the event. Not Related: There is not a temporal or causal relationship to the study drug administration.  
Protocol  COL.AOM.2013.002 
 
Page 42 of 76 
Final Protocol: 29 July 2013 [IP_ADDRESS] Serious Adverse Events and Other Events of Interest A serious adverse event (SAE) is any untoward medical occurrence that at any dose: ● Results in death ● Is life-threatening (i.e., the subject was at immediate risk of death from the adverse event as it occurred; this does not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death) ● Requires inpatient hospi[INVESTIGATOR_1081] ● Results in persistent or significant disability/incapacity ● Is a congenital anomaly/birth defect (in the child of a subject who was exposed to the study drug) Other important medical events that may not be immediately life-threatening or result in death or hospi[INVESTIGATOR_313], when based on appropriate medical judgment, may jeopardize the subject or may require intervention to prevent one of the outcomes in the definition of SAE listed above should also be considered SAEs.  Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in such situations.  In addition to the above, other events of interest include pregnancy or exposure to study drug through breastfeeding; AEs associated with study drug overdose, misuse, abuse, or medication error; and any treatment-emergent significant laboratory abnormality.  These events of interest are to be captured using the SAE procedures but are to be considered SAEs only if they meet one of the above criteria.  All AEs associated with events of interest are to be reported on the CRF whether or not they meet the criteria for SAEs. The following hospi[INVESTIGATOR_3517] “adverse event” (i.e., there is no untoward medical occurrence) associated with the hospi[INVESTIGATOR_059]: ● Hospi[INVESTIGATOR_3095]  ● Planned hospi[INVESTIGATOR_3518] ● Hospi[INVESTIGATOR_3097] (where the condition requiring the hospi[INVESTIGATOR_81403]) ● Hospi[INVESTIGATOR_123204] ● Hospi[INVESTIGATOR_3521] a device (e.g., battery replacement) that was in place before study entry 
Protocol  COL.AOM.2013.002 
 
Page 43 of 76 
Final Protocol: 29 July 2013 [IP_ADDRESS] Other Safety Assessments [IP_ADDRESS].[ADDRESS_138649] recent injection site will be completed at each visit at which an injection is administered:  an investigator assessment and a subject-rated visual analog scale (VAS) assessment of the pain at the injection site. For the investigator assessment, the investigator, or qualified designee, will assess the injection site for localized pain, redness, swelling, and induration.  For the subject-rated VAS assessment, the subject will mark the scale with one vertical line across the bar of the VAS to indicate the degree of injection site discomfort. These assessments will occur as the last evaluations of the visit, approximately 1 hour (± 15 minutes) after the gluteal IM once monthly injection. For the subject-rated assessment of pain at the injection site, the subject will complete the VAS approximately 1 hour (± 15 minutes) post-injection to assess the injection site. The evaluations must be completed on the same day (i.e., the day the injection is administered). [IP_ADDRESS].[ADDRESS_138650] circumference. The calculation for BMI is: weight (kg) [height (m)]2  [IP_ADDRESS].3 Vital Signs Vital sign measurements (i.e., systolic and diastolic blood pressure [BP] [mmHg], pulse [beats per minute], respi[INVESTIGATOR_697] [per minute], body temperature [in centigrade]), and weight (kg) will be obtained at the visits designated on the Schedules of Assessments (Table 4 through Table 6) by a validated method.  Blood pressure and pulse will be measured after the subject has been supi[INVESTIGATOR_2525] 5 minutes.  All BP measurements should be performed on the same arm, preferably by [CONTACT_3194]. [IP_ADDRESS].4 Schizophrenia Assessments DSM-IV-TR Global Assessment of Functioning (GAF) The GAF is used to assess global functioning using a scale from 1 (worst) to 100 (best).  An intraclass correlation coefficient of 0.81 has been reported. Structured Clinical Interview for DSM-IV, Patient Version (SCID-P) 
Protocol  COL.AOM.2013.002 
 
Page 44 of 76 
Final Protocol: [ADDRESS_138651] sections begin with an entry question that would allow the interviewer to "skip" the associated questions if not met. However, to be sensitive to subthreshold syndromes we will query further even if the entry questions appears negative.  For all diagnoses symptoms are coded as present, subthreshold, or absent.  [IP_ADDRESS].5 Suicidality Clinical Global Impression – Severity of Suicidality (CGI-SS) The CGI-SS is a two-part scale that assesses severity of suicidality over the week prior to the evaluation. The CGI-SS Part 1 has 5 levels of severity of suicidality: 1   =   not at all suicidal, 2   =   mildly suicidal, 3   =   moderately suicidal, 4   =   severely suicidal, and 5   =   attempted suicide. The CGI-SS Part 2 has 7 levels of change in suicidality: 1 = very much improved since the initiation of treatment, 2 = much improved, 3 = minimally improved, 4 = no change since the initiation of treatment, 5=minimally worse, 6= much worse, 7=very much worse since the initiation of treatment. All evaluations for Part 2 of the CGI-SS will use the baseline of the appropriate phase as a reference for judging change in suicidality.  For the purpose of this study, a score of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or a score of 6 (much worse) or 7 (very much worse) on Part 2 will be considered an exacerbation of psychotic symptoms/impending relapse and may result in immediate withdrawal from the study at the investigator’s discretion. Columbia Suicide Severity Rating Scale (C-SSRS) The C-SSRS was designed to distinguish the domains of suicidal ideation and suicidal behavior.  The C-SSRS scale consists of a baseline evaluation that assesses the lifetime experience of the subject with suicide events and suicidal ideation and a post-baseline/”Since Last Visit” evaluation that focuses on suicidality since the last study visit.  The baseline C-SSRS form will be completed at baseline of Phase 1.  The “Since Last Visit” C-SSRS form will be completed at all subsequent visits. Four constructs are measured: 1. The severity of ideation (the “severity subscale”), which is rated on a 5-point ordinal scale in which 1 = wish to be dead, 2 = nonspecific active suicidal thoughts, 3 = suicidal thoughts with methods, 4 = suicidal intent, and 5 = suicidal intent with plan.  2. The intensity of ideation subscale (the “intensity subscale”), which comprises 5 items, each rated on a 5-point ordinal scale: frequency, duration, controllability, deterrents, and reason for ideation.  
Protocol  COL.AOM.2013.002 
 
Page 45 of 76 
Final Protocol: 29 July 2013 3. The behavior subscale, which is rated on a nominal scale that includes actual, aborted, and interrupted attempts; preparatory behavior; and nonsuicidal self-injurious behavior.  4. The lethality subscale, which assesses actual attempts; actual lethality is rated on a 6-point ordinal scale, and if actual lethality is 0, potential lethality of attempts is rated on a 3-point ordinal scale. [IP_ADDRESS].[ADDRESS_138652] and his/her partner(s) are sterile (i.e., women who have had an oophorectomy and/or hysterectomy or have been postmenopausal for at least 12 consecutive months; or men who have had orchiectomy) or remain abstinent, two of the following precautions must be used: vasectomy, tubal ligation, vaginal diaphragm, IUD, birth control pi[INVESTIGATOR_3353], birth control depot injection, birth control implant, condom, or sponge with spermicide.  Any single method of birth control, including vasectomy and tubal ligation, may fail, leading to pregnancy. Before enrolling women of child-bearing potential in this clinical study, investigators must review guidelines about trial participation for women of childbearing potential.  The topi[INVESTIGATOR_78609]: • General information • Informed consent form • Pregnancy prevention information • Drug interactions with hormonal contraceptives • Contraceptives in current use • Guidelines for the follow-up of a reported pregnancy. Prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy.  The subject must sign an ICF stating that the above-mentioned risk factors and the consequences were discussed with her. [IP_ADDRESS].7 Urine Screen for Drugs of Abuse A 30-mL urine sample will be collected at designated time points as specified in the Schedules of Assessments (Table 4 through Table 6).  This sample will be tested for drugs of abuse: e.g., marijuana, cocaine, opi[INVESTIGATOR_858], oxycodone, phencyclidine, amphetamines, barbiturates, benzodiazapi[INVESTIGATOR_1651], methadone, and propoxyphene (ARUP laboratories; see Section 6).  An aliquot 
Protocol  COL.AOM.2013.002 
 
Page 46 of 76 
Final Protocol: 29 July 2013 of the urine sample will be prepared and shipped for confirmation and quantification of drug levels via enzyme immunoassay/gas chromatography-mass spectrometry/liquid chromatography-tandem mass spectrometry. In addition, a blood sample will be obtained to test for blood alcohol content. [IP_ADDRESS].8 Monitoring of Side Effects Scale (MOSES) The MOSES scale is a Division of Social and Health Services Scale consisting of seven body system symptom domains: ears, eyes, head; mouth; nose, throat, chest; gastrointestinal; musculoskeletal and neurological; skin; and urinary and genital; and one psychological symptom domain, in which the examiner will check boxes for symptoms present on a scale of 0 to 4 in which 0 = none and 4 = severe. [IP_ADDRESS] Efficacy Assessments – Clinical Outcome [IP_ADDRESS].1 Clinical Global Impression – Improvement The efficacy of study medication will be rated for each subject using the CGI-I scale.  The rater or investigator will rate the subject’s total improvement whether or not it is due entirely to drug treatment.  All responses will be compared to the subject’s condition at baseline of the appropriate phase.  The CGI-I during Phase B should be assessed relative to the subject’s condition at the Phase B baseline visit.  Response choices include:  0 = not assessed; 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; and 7 = very much worse.  [IP_ADDRESS].2 Clinical Global Impression – Severity The severity of illness for each subject will be rated using the CGI-S scale.  To assess CGI-S, the rater or investigator will answer the following question: “Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?” Response choices include: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. [IP_ADDRESS].3 Positive and Negative Syndrome Scale (PANSS) The PANSS consists of three subscales containing a total of [ADDRESS_138653], severity is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.  The symptom constructs for each subscale are as follows: Positive Subscale (7 positive symptom constructs:  delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspi[INVESTIGATOR_23703]/persecution, and hostility), Negative Subscale (7 negative symptom constructs:  blunted affect, emotional withdrawal, poor rapport, passive pathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking),  
Protocol  COL.AOM.2013.002 
 
Page 47 of 76 
Final Protocol: 29 July 2013 General Psychopathology Subscale (16 symptom constructs:  somatic concern, anxiety, guilt feelings, tension, mannerism and posturing, depression, motor retardation, uncooperative, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance). All efforts are to be made to ensure that the same rater administers the PANSS for a given subject.  The number of raters within each study center is to be kept to a minimum.  Instructions for administering this instrument will be provided to the site.  A copy of the PANSS assessment with complete rating criteria is required as source documentation.  [IP_ADDRESS] Efficacy Assessments – Extrapyramidal Symptoms [IP_ADDRESS].1 Abnormal Involuntary Movement Scale (AIMS) The AIMS assessment consists of 10 items describing symptoms of dyskinesia.  Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7) will be observed unobtrusively while the subject is at rest (e.g., in the waiting room), and the investigator will also make global judgments on the subject’s dyskinesias (items 8 through 10).  Each item will be rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, awareness/severe distress). [IP_ADDRESS].2 Barnes Akathisia Rating Scale (BARS) The BARS assessment consists of 4 items related to akathisia: objective observation of akathisia by [CONTACT_093], subjective feelings of restlessness by [CONTACT_423], subject distress due to akathisia, and global evaluation of akathisia.  The first 3 items will be rated on a 4-point scale, with a score of 0 representing absence of symptoms and a score of 3 representing a severe condition.  The global clinical evaluation will be made on a 6-point scale, with 0 representing absence of symptoms and a score of 5 representing severe akathisia. [IP_ADDRESS].3 Simpson Angus Scale (SAS) The SAS assessment consists of a list of 10 symptoms of parkinsonism (gait, arm droppi[INVESTIGATOR_007], shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia).  Each item is rated on a 5-point scale, with a score of 1 representing absence of symptoms, and a score of 5 representing a severe condition.  The SAS Total Score is the sum of the scores for all 10 items. [IP_ADDRESS] Efficacy Assessments – Mood [IP_ADDRESS].1 The Hamilton Anxiety Scale (HAM-A) Rating scale developed to quantify the severity of anxiety symptomatology, often used in psychotropic drug evaluations. 
Protocol  COL.AOM.2013.002 
 
Page 48 of 76 
Final Protocol: 29 July 2013 [IP_ADDRESS].2 The Hamilton Depression Rating Scale (HAM-D) Proven useful for determining the level of depression before, during, and after treatment32.  It is based on the clinician's interview with the patient and probes symptoms such as depressed mood, guilty feelings, suicidal ideation, sleep disturbances, anxiety levels and weight loss.  Research has demonstrated a validity coefficient of .85. [IP_ADDRESS].3 The Profile of Mood States (POMS) Self-report inventory in which respondents rate a series of mood states.  The POMS Standard form contains [ADDRESS_138654] ranged from .84 to .95. [IP_ADDRESS] Efficacy Assessments – Medication Adherence [IP_ADDRESS].1 Medication Adherence Questionnaire (MAQ) The MAQ is a validated, 4-item, self-reported measure to determine adherence to treatment.  The four behavioral questions of the MAQ are designed to assess different sources of noncompliance (e.g., forgetfulness, carelessness, symptom driven compliance), with positive responses indicating nonadherence to medication regimens.  Responses to each question will be “Yes” (score of 1) or “No” (score of 0), thus the MAQ total score will range from 0 to 4. [IP_ADDRESS].2 Medication Possession Ratio (MPR) Medication Possession Ratio (MPR) measures the percentage of time a subject has access to medication.   [IP_ADDRESS] Other Assessments [IP_ADDRESS].[ADDRESS_138655] is asked to indicate when this has happened by [CONTACT_7326] a “yes” button.  Subjects are instructed to make this indication as quickly as possible.  If the subject fails to make an indication, or presses the button prior to the face of the card becoming visible, an error sound is heard. Choice Reaction Time Choice reaction time will be assessed by [CONTACT_123269].  This task is used to assess visual attention as well as vigilance.  This task is presented similar to the simple reaction time task with the additional instruction that the 
Protocol  COL.AOM.2013.002 
 
Page 49 of 76 
Final Protocol: [ADDRESS_138656] only presses the “yes” button when the card presented is red.  As with the previous task, subjects are instructed to make this indication as quickly as possible. One-back Working Memory The one back task is a CogState task that will be used to assess attention and working memory.  During this task, subjects are presented with an electronic deck of cards face down.  A card is turned over revealing the face of the card and then is returned to the deck.  Following each card, the subject is instructed to indicate whether or not the most recent card is identical to the previous card by [CONTACT_123270] “yes” or “no” on the keyboard.  The subject is encouraged to work quickly and accurately. Set Shifting This test is a Cog State test designed to determine executive function.  During this task, the subject is presented with a playing card in the center of the computer screen.  The subject is asked to guess whether the card is the “target” or “correct” card.  A target card is a card which contains a color or a number.  If the guess is correct the card is flipped over. If not correct, an error noise will sound and the card will not flip over.  At this point, the subject must guess again. Once the subject has made their way through a set of cards, the target or correct stimulus dimensions changes without the subject’s knowledge and the subject must relearn the rule.  There are multiple set shifts within the task, and the order of the set shifts is pseudo-randomized to create multiple alternate forms of the task. Unit of measurement: total number of errors.  Accuracy of performance and total number of errors across five rounds are measured; a lower score = better performance OTHER NEUROPSYCHOLOGICAL TESTS TrailMaking Test This test is designed to measure visual conceptual and visual-motor tracking, as well as maintenance of cognitive set.  The subject must first draw lines to connect consecutively numbered circles on one work sheet (Part A) and then connect the same number of consecutively numbered and lettered circles on another work sheet by [CONTACT_123271] (Part B).  TrailMaking B is the more sensitive of the two tests -- particularly to frontal-lobe dysfunction -- as scores on this section are indicative of the subject's ability to shift sets and process concurrent stimuli. Tower of London The Tower of London task will be used to assess executive function.  This assessment will be presented electronically during with the subject will be presented with a screenshot containing three balls of differing colors on three pegs.  The subject will be asked the amount of times the balls in one pi[INVESTIGATOR_123205] a second image.  The complexity of the task will increase over the course of the trials. Continuous Performance Test (CPT) 
Protocol  COL.AOM.2013.002 
 
Page 50 of 76 
Final Protocol: [ADDRESS_138657] Assesses a person’s ability to form abstract concepts, utilize feedback, and shift and maintain set.  This test has been shown to be sensitive to frontal lobe dysfunction.  Dependent variables include total number of categories correct (color, form, or number) and perseverative errors.  The measure has a test retest generalizability coefficient of > 90. [IP_ADDRESS].[ADDRESS_138658] (FAST):  The FAST is a 24-item, clinician administered assessment used to assess functional impairment with a focus on the main problems experienced by [CONTACT_123272].  The timeframe for this measure refers to the subjects last 15 days before assessment.  The assessment is broken down into 6 specific areas of functioning including:  autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships, and leisure time. QUALITY OF LIFE SCALE (QOLS):  The QOLS is a measure designed to determine the impact of health care.  This measure consists of 16 questions (the original 15 QOLS questions, with the addition of a chronic illness component) delivered as a self-report measure.  The QOLS assesses factors related to (1) relationships and material well-being, (2) personal, social and community commitment, and (3) health and functioning. SOCIAL AND OCCUPATIONAL FUNCTIONING ASSESSMENT SCALE (SOFAS):  The SOFAS is a new scale that assesses a subject’s individual level of social and occupational functioning.  Similar to the GAF, the SOFAS is a scaled score that ranges from [ADDRESS_138659]’s psychiatric illness symptom severity.  This scale can be used in terms of current functioning, but can also be used over a timeframe detailing highest and lowest level of social and occupational functioning. LIFE FUNCTIONING QUESTIONNAIRE (LFQ):  The LFQ is a 14-item, gender-neutral, self-report questionnaire used to assess functional outcome in patients with psychiatric illness in terms of role function.  The assessment measures four domains, which include:  workplace, duties at home, leisure time with family, and leisure time with friends. HOLLINGSHEAD FOUR FACTOR INDEX OF SOCIAL POSITION:  The Hollingshead Index is a report of socioeconomic status, used with modifications.  Intermeasure correlations range from r = .86 to .91. 
Protocol  COL.AOM.2013.002 
 
Page 51 of 76 
Final Protocol: 29 July 2013 [IP_ADDRESS] Pharmacokinetic/Pharmacodynamic Assessments PHARMACOKINETIC ASSESSMENTS Not applicable. PHARMACODYNAMIC ASSESSMENTS Measurements of FA, BPF, and proton metabolites will occur using imaging techniques as described below.  All structural scans will be read and interpreted by a clinical neuroradiologist.  Structural data will be utilized in three ways: to ensure specific regions of interest are visible and localized for correlation with T1 mappi[INVESTIGATOR_123206], DT-MRI and MRS data.  In addition, cortical reconstruction and volumetric segmentation and parcellation will be performed with the FreeSurfer image analysis suite, which is documented and available for download online (http://surfer.nmr.mgh.harvard.edu/), to obtain volumetric and cortical thickness measures for brain regions of interest, including the cingulum.  Magnetic Resonance Imaging All subjects will undergo an MRI protocol on a Siemens Trio 3 Tesla Scanner at baseline, 6 months, and 12 months during Phase C.  This protocol includes a high-resolution structural MRI protocol.  The structural acquisitions include a T1-weighted 3D magnetization prepared rapid acquisition gradient echo (MPRAGE) sequence acquired sagittally, with TE/TR/TI = 3.38ms/2.0s/1.1s, 8°flip, 256 x 256 acquisition matrix, 256 mm2 field of vision, 160 slices, 1.0 mm slice thickness.   Diffusion Tensor Imaging (DT-MRI)  A single-shot spin-echo echo-planar imaging (EPI) sequence with diffusion-weighting will be used to acquire diffusion tensor images.  To describe the intensity and direction of diffusion anisotropy, MR images with 25 non-collinear diffusion gradients and without diffusion gradient will be acquired.  B-factor will be set to be 1000 sec/mm2.  Acquisition parameters include FOV = 256 mm, matrix = [ADDRESS_138660] resolution.  TR/TE = 7000/84, pi[INVESTIGATOR_123207] = 1346 Hz, and averages = 4.  Magnetic Resonance Spectroscopic (MRS) Imaging  Proton (1H) magnetic resonance spectroscopic imaging measurements will be acquired using a 3.0 Tesla Siemens (Erlangen, [LOCATION_013]) VerioTM whole-body MRI scanner.  1H-MRS spectra will be acquired using a manufacturer-supplied 12-channel head coil, following high-resolution MPRAGE image acquisition to facilitate accurate voxel positioning. A modified point-resolved spectroscopy  sequence (two-dimensional J-resolved spectroscopy) is used:  repetition time/echo time (TR/TE) range 2400/31 to 229 ms; 100 TE steps; Vector size 2048; Bandwidth 2000/500 Hz) acquires MRS spectra with 128 and 4 signal averages per TE step for metabolite and water non-suppressed data. An 18.75 mL (2.5 x 2.5 x 3.0 cm3) voxel is placed at the ACC and the parietal-occipi[INVESTIGATOR_96067]. Parietal occipi[INVESTIGATOR_123208] a control region. Automated and manual shimming ensures unsuppressed water signal linewidths of <9 Hz. 
Protocol  COL.AOM.2013.002 
 
Page 52 of 76 
Final Protocol: 29 July 2013 9.5.2 Schedules of Assessments Table 4 provides the Schedule of Assessments for Phase A of the study.  Table 5 provides the Schedule of Assessments for Phase B of the study.  Table 6 provides the Schedule of Assessments for Phase C of the study.  Table 7 provides the neurological assessments to be completed During Phase C.  
Protocol  COL.AOM.2013.002 
 
Page 53 of 76 
Final Protocol: 29 July 2013 Table 4 Schedule of Assessments – Phase A – Screening and Conversion Phase Assessments STUDY VISIT Screening (Days -7 to -2) Conversion to Oral Aripi[INVESTIGATOR_4253] (Phase A) Baseline Day 1i Week 1 Week 2 Week 3 Week 4 Week 5 Week 6g ± [ADDRESS_138661] STUDY ASSESSMENTS Informed consent X        Review inclusion/exclusion criteria X       X Medical history X        Demographics X        Physical examination, including height X       X Vital signs X X X X X X X X Body weight and waist circumference  X      X Calculate BMIa  X      X 12-lead ECG X       X Clinical laboratory testsb X       X Prolactin level X       X Urine βhCGc X       X Screen for drugs of abused X       X Prior medication history X        Concomitant medications X X X X X X X X Adverse events X X X X X X X X SCHIZOPHRENIA-RELATED ASSESSMENTS SCID-P X        Current antipsychotic therapye X X X X X X X X Clinical Outcome CGI-I, CGI-S , CGI-SS, C-SSRS, GAF, MAQ, PANSS X X X X X X X X Mood HAM-A, HAM-B, POMS X X X X X X X X Extrapyramidal Side Effects AIMS, BARS, SAS X X X X X X X X 
Protocol  COL.AOM.2013.002 
 
Page 54 of 76 
Final Protocol: 29 July 2013 Table 4 Schedule of Assessments – Phase A – Screening and Conversion Phase Assessments STUDY VISIT Screening (Days -7 to -2) Conversion to Oral Aripi[INVESTIGATOR_4253] (Phase A) Baseline Day 1i Week 1 Week 2 Week 3 Week 4 Week 5 Week 6g ± 2 days Adverse Drug Effects MOSES X X X X X X X X CONVERSION TO ARIPI[INVESTIGATOR_123209]  X X X X X X X Cross-titrationh  X X X X X X  Taper off other psychotropic medicationsf  X X X X X X X Assess eligibility for Phase B    X X X X X AIMS = Abnormal Involuntary Movement Scale, ALT = alanine aminotransferase, AST = aspartate aminotransferase, βhCG = human chorionic gonadotropin, BARS = Barnes Akathesia Rating Scale, BMI = body mass index, BUN = blood urea nitrogen, CGI-I = clinical and global Impression – Improvement, CGI-S = Clinical and Global Impression – Severity, CGI-SS = Clinical and Global Impression for Severity of Suicidality, C-SSRS = Columbia Suicide Severity Rating Scale, CYP = cytochrome P, DSM = Diagnostic and Statistical Manual, ECG = electrocardiogram, GAF = DSM-IV-TR Global Assessment of Functioning, GGT = gamma glutamyltransferase, HAM-A = Hamilton Anxiety Scale, HAM-D = Hamilton Depression Rating Scale, LDH – lactate dehydrogenase, MAQ = Medication Adherence Questionnaire, MOSES = Monitoring of Side Effects Scale,  PANSS = Positive and Negative Symptom Scale, POMS = Profile of Mood States, RBC = red blood cell, SAS = Simpson Angus Scale, SCID-P = structured clinical interview for DSM-IV Patient Version, WBC = white blood cell a:  BMI is calculated as:  mass (kg)/height (m2) b:  clinical laboratory tests include hematology (WBC with differential, RBC, hemoglobin, hematocrit, mean corpuscular volume and mean corpuscular hemoglobin concentration), serum chemistry (ALT, alkaline phosphatase, AST, total bilirubin, BUN, calcium, cholesterol, creatinine, GGT, glucose, LDH, potassium, total protein, sodium, and triglycerides), and urinalysis (color, appearance, specific gravity, pH, microscopic for RBCs and WBCs per high-powered field. c: Urine pregnancy test for women of childbearing potential only. If a subject or investigator suspects that the subject may be pregnant, a serum pregnancy test should be performed. d:  Urine will be collected for drugs of abuse testing for:  marijuana, cocaine, opi[INVESTIGATOR_858], oxycodone, phencyclidine, amphetamines, barbiturates, benzodiazapi[INVESTIGATOR_1651], methadone, and propoxyphene on the day of MR imaging (ARUP Drugs of Abuse Panel 9:  ARUP Laboratories, Salt Lake City, UT).  An aliquot of this urine sample will also be sent for confirmation and quantification of drug levels via Enzyme Immunoassay/Gas Chromatography-Mass Spectrometry/Liquid Chromatography-Tandem Mass Spectrometry.  Note:  the presence of benzodiazapi[INVESTIGATOR_123210]’s treatment regimen; subjects will be excluded for significant substance use per the investigator’s discretion. In addition, blood will be collected to test for blood alcohol content. e:  Subjects with schizophrenia only f:  Subjects on SOC oral antipsychotic medications that areparticipating in Phase A due to  washout from more than one benzodiazepi[INVESTIGATOR_050], or prohibited concomitant medications such as CYP3A4 inducers, antidepressants including monamine oxidase inhibitors, and mood stabilizers, will also be evaluated during Phase A.  g:  The final visit of Phase A will be the baseline for Phase B for those subjects whoparticpated in Phase A. h:  For subjects with schizophrenia only, who were randomized to the aripi[INVESTIGATOR_123211] C and aren’t currently receiving oral aripi[INVESTIGATOR_123107]. i:  Screening and baseline can occur on the same day if appropriate. 
Protocol  COL.AOM.2013.002 
 
Page 55 of 76 
Final Protocol: 29 July 2013 Table 5: Schedule of Assessments Phase B – Oral Stabilization Phase Assessments Baselinea Week 2b Week 4h Week  6c,h Week 8c,h Week 10c,h Week 12c,h (± 1 day) STANDARD STUDY ASSESSMENTS Confirm inclusion/exclusion criteria X      X Physical examination, including height  X      X Vital signs X X X X X X X 12-lead ECG X      X Body weight and waist circumference X X X X X X X Calculate BMId X  X  X  X Clinical laboratory testse X      X Prolactin concentration X      X Urine βhCGf X  X  X  X Screen for drugs of abuseg X  X  X  X Concomitant medications X X X X X X X Adverse events  X X X X X X X SCHIZOPHRENIA-RELATED STUDY ASSESSMENTS CLINICAL OUTCOME CGI-I, MAQ, PANSS  X X X X X X X MOOD SCALES HAM-A, HAM-D, POMS        EXTRAPYRAMIDAL SIDE EFFECTS AIMS, BARS, SAS        ADVERSE DRUG EFFECTS MOSES        BASELINE ASSESSMENTS FOR PHASE C Neuropsychological Testingi        Functional Outcomes Assessmentsj        STUDY MANAGEMENT Assess stability criteria  X X X X X X Drug accountability (MPR)  X X X X X X Administer aripi[INVESTIGATOR_123212],i       X Evaluate injection sitej       X AIMS = Abnormal Involuntary Movement Scale, ALT = alanine aminotransferase, AST = aspartate aminotransferase, βhCG = human chorionic gonadotropin,  BARS = Barnes Akathisia Rating Scale, BMI = body mass index, BUN = blood urea nitrogen, CGI-I = Clinical and Global Impression – Improvement,  C-SSRS = Columbia Suicide Severity Rating Scale, ECG = electrocardiogram, GGT = gamma glutamyltransferase, HAM-A = Hamilton Anxiety Scale,  HAM-D =  Hamilton Depression Rating Scale, IM = intramuscular, LDH – lactate dehydrogenase,  
Protocol  COL.AOM.2013.002 
 
Page 56 of 76 
Final Protocol: 29 July 2013 Table 5: Schedule of Assessments Phase B – Oral Stabilization Phase MAQ = Medication Adherence Questionnaire, MPR = medicine possession ratio, MOSES =  Monitoring of Side Effects Scale, MRI = magnetic resonance imaging, PANSS = Positive and Negative Syndrome Scale,POMS = Profile of Mood States, RBC = red blood cell, SAS = Simpson Angus Scale, VAS = visual analog scale, WBC = white blood cell a:  For subjects not converting to oral aripi[INVESTIGATOR_99546], subjects move directly to Phase B after screening. Screening and baseline can occur on the same day if appropriate. b:  For subjects who participated in Phase A, baseline assessments are completed during the last visit of Phase A; Week [ADDRESS_138662] visit of Phase B c:  Subjects who are stable for 2 consecutive visits can be moved directly into Phase C; subjects unable to be stabilized after 12 weeks will be discontinued from the study d:  BMI is calculated as:  mass (kg)/height (m2) e:  Clinical laboratory tests include hematology (WBC with differential, RBC, hemoglobin, hematocrit, mean corpuscular volume and mean corpuscular hemoglobin concentration), serum chemistry (ALT, alkaline phosphatase, AST, total bilirubin, BUN, calcium, cholesterol, creatinine, GGT, glucose, LDH, potassium, total protein, sodium, and triglycerides), and urinalysis (color, appearance, specific gravity, pH, microscopic for RBCs and WBCs per high-powered field). f:  Urine pregnancy test for women of childbearing potential only. If a subject or investigator suspects that the subject may be pregnant, a serum pregnancy test should be performed. g:  Urine will be collected for drugs of abuse testing for:  marijuana, cocaine, opi[INVESTIGATOR_858], oxycodone, phencyclidine, amphetamines, barbiturates, benzodiazapi[INVESTIGATOR_1651], methadone, and propoxyphene on the day of MR imaging (ARUP Drugs of Abuse Panel 9:  ARUP Laboratories, Salt Lake City, UT).  An aliquot of this urine sample will also be sent for confirmation and quantification of drug levels via Enzyme Immunoassay/Gas Chromatography-Mass Spectrometry/Liquid Chromatography-Tandem Mass Spectrometry.  Note:  the presence of benzodiazapi[INVESTIGATOR_123210]’s treatment regimen.  A subject will be excluded for significant substance use per the investigators discretion.  In addition, blood will be collected to test for blood alcohol content. h:  The final visit of Phase B will be the Baseline visit for Phase C.  Neuropsychological testing, functional outcomes testing, and the first dose of aripi[INVESTIGATOR_123213].  MRI will be completed. i:  Neuropsychological testing includes:  CogState testing (simple reaction time, choice reaction time, one-back working memory, two-back working memory, and set shifting), TrailMaking Test, Tower of London, Continuous Performance Test, and Wisconsin Card Sorting Test.  See Table 7. j:  Functional outcomes assessments include:  Functional Assessment Test, Quality of Life Scale, Social and Occupational Functioning Assessment Scale, Life Functioning Questionnaire k:  For subjects who are entering into Phase C and are randomized to aripi[INVESTIGATOR_123104], the first dose of aripi[INVESTIGATOR_123214] B.  All study drug will be administered at the end of the visit.    
Protocol  COL.AOM.2013.002 
 
Page 57 of 76 
Final Protocol: 29 July 2013 Table 6: Schedule of Assessments Phase C - Treatment Phase Assessments Study Week 1 2 3 4 6 8 10 12 16 20 24 28 32 36 40 44 48 52 (± 3 days) STANDARD STUDY ASSESSMENTS Physical examination           X       X Vital signs X X X X X X X X X X X X X X X X X X Body weight and waist circumference X X X X X X X X X X X X X X X X X X BMIa X   X  X  X X X X X X X X X X X 12-lead ECG           X       X Clinical laboratory testsb           X       X Prolactin level           X       X Urine Pregnancy testc    X  X  X X X X X X X X X X X Screen for drugs of abused        X   X        VAS pain at injection sitee    X  X  X X X X X X X X X X X Investigator rating of injection sitee    X  X  X X X X X X X X X X X Concomitant medications X X X X X X X X X X X X X X X X X X Adverse events X X X X X X X X X X X X X X X X X X SCHIZOPHRENIA-RELATED ASSESSMENTS CLINICAL OUTCOME CGI-I, CGI-S , CGI-SS, C-SSRS, GAF, MAQ, PANSS        X   X   X   X X MOOD SCALES HAM-A, HAM-D, POMS X   X  X  X X X X X X X X X X X EXTRAPYRAMIDAL SIDE EFFECTS AIMS, BARS, SAS    X  X  X X X X X X X X X X X ADVERSE DRUG EFFECTS MOSES X X X X X X X X X X X X X X X X X X STUDY-SPECIFIC ASSESSMENTS AND MANAGEMENT Assess stability criteriag X X X X X X X X X X X X X X X X X  MRI Imaging Xi          X       X Administer IM once monthly aripi[INVESTIGATOR_123215]    X  X  X X X X X X X X X X  Drug accountability with SOC oral anti-psychotics (MPR) X X X X X X X X X X X X X X X X X X 
Protocol  COL.AOM.2013.002 
 
Page 58 of 76 
Final Protocol: 29 July 2013 Table 6: Schedule of Assessments Phase C - Treatment Phase Assessments Study Week 1 2 3 4 6 8 10 12 16 20 24 28 32 36 40 44 48 52 (± 3 days) AIMS = Abnormal Involuntary Movement Scale, ALT = alanine aminotransferase, AST = aspartate aminotransferase, βhCG = human chorionic gonadotropin, BARS = Barnes Akathesia Rating Scale, BMI = body mass index, BUN = blood urea nitrogen, CGI-I = clinical and global Impression – Improvement, CGI-S = Clinical and Global Impression – Severity, CGI-SS = Clinical and Global Impression for Severity of Suicidality, C-SSRS = Columbia Suicide Severity Rating Scale, DSM = Diagnostic and Statistical Manual, DT-MRI = diffusion tensor magnetic resonance imaging, ECG = electrocardiogram, EPS = extrapyramidal side effects, fMRI = functional magnetic resonance imaging, GGT = gamma glutamyltransferase, HAM-A = Hamilton Anxiety Scale, HAM-D = Hamilton Depression Rating Scale, LDH – lactose dehydrogenase, MAQ = Medication Adherence Questionnaire, MOSES = Monitoring of Side Effects Scale, MPR = medication possession ratio, MRI = magnetic resonance imaging, MRS = magnetic resonance spectroscopy, PANSS = Positive and Negative Symptom Scale, POMS = Profile of Mood States, RBC = red blood cell, SAS = Simpson Angus Scale, WBC = white blood cell a:  BMI is calculated as:  mass (kg)/height (m2)  b:  clinical laboratory tests include hematology (WBC with differential, RBC, hemoglobin, hematocrit, mean corpuscular volume and mean corpuscular hemoglobin concentration), serum chemistry (ALT, alkaline phosphatase, AST, total bilirubin, BUN, calcium, cholesterol, creatinine, GGT, glucose, LDH, potassium, total protein, sodium, and triglycerides), and urinalysis (color, appearance, specific gravity, pH, microscopic for RBCs and WBCs per high-powered field. c:  Urine pregnancy test for women of childbearing potential only. If a subject or investigator suspects that the subject may be pregnant, a serum pregnancy test should be performed.  d:  Drug screen for drugs of abuse includes:  amphetamines, barbiturates, benzodiazapi[INVESTIGATOR_1651], cannabinoids, cocaine metabolites, opi[INVESTIGATOR_858], ethanol, and methadone.  Note:  the presence of benzodiazapi[INVESTIGATOR_123210]’s treatment regimen. e:  For subjects administered once monthly aripi[INVESTIGATOR_92666].  For visits at which no injection is administered, the assessments are done once, using the most recent injection site.  For visits in which an injection is administered, the area of the most recent injection will be assessed approximately 30 minutes prior to the injection (or in the case of the first injection, the area to be injected), and one hour (± 15 minutes) after the injection.  On injection days, these assessments will be the last assessments completed. f:  Neuropsychological testing includes: CogState testing (simple reaction time, choice reaction time, one-back working memory, two-back working memory, and set shifting), TrailMaking Test, Tower of London, Cognitive Performance Test, and Wisconsin Card Sorting Test.  See Table 7. g:  Functional outcomes assessments include:  Functional Assessment Test, Quality of Life Scale, Social and Occupational Functioning Assessment Scale, Life functioning Questionnaire h:  aripi[INVESTIGATOR_123216] i:  MRI imaging includes MRI, MRS, fMRI, DT-MRI 
Protocol  COL.AOM.2013.002 
 
Page 59 of 76 
Final Protocol: 29 July 2013 Table 7: Neuropsychological Measures for the Treatment Phase (Phase C) Neuropsychological Measure Baseline [ADDRESS_138663] X X X CPT = Continuous Performance Test, WCST = Wisconsin Card Sorting Test   9.5.[ADDRESS_138664] [IP_ADDRESS] Reporting of Serious Adverse Events All serious adverse events, regardless of their relationship to study treatment, must be reported to OAPI [INVESTIGATOR_2394] a completed SAE form by [CONTACT_36600] [ADDRESS_138665] information for reporting of SAEs is provided in the Investigator Study File. Report IREs (serious adverse events, potential Hy’s Law cases, pregnancies and adverse events requiring discontinuation of trial drug) to: Clinical Safety and Pharmacovigilance Otsuka Pharmaceutical Development & Commercialization, Inc.  Khaled Bannout, MD 
Protocol  COL.AOM.2013.002 
 
Page 60 of 76 
Final Protocol: [ADDRESS_138666]  Rockville, Maryland  [ZIP_CODE], [LOCATION_002] Hotline:  [PHONE_2795] Fax:  [PHONE_2796]  For Medical Emergencies (use only if Otsuka personnel listed above are unavailable):  [PHONE_2165] It is very important that the SAE report form be filled out as completely as possible at the time of the initial report.  This includes the investigator’s assessment of causality. Any follow-up information received on SAEs should be forwarded within 1 business day of its receipt.  If the follow-up information changes the investigator’s assessment of causality, this should also be noted on the follow-up SAE form. Preliminary SAE reports should be followed as soon as possible by [CONTACT_123273][INVESTIGATOR_3103], autopsy reports, and other documents requested by [CONTACT_456]. The investigator must notify his/her IRB of the occurrence of the SAE, in writing, if required by [CONTACT_1385].  A copy of this communication must be forwarded to the OAPI [INVESTIGATOR_123217]. [IP_ADDRESS] Immediately Reportable Events (IRE) Immediately Reportable Event (IRE): • Any SAE • Any AE that necessitates discontinuation of study drug • Potential Hy’s Law cases (any increase of AST or ALT ≥ 3 times the upper normal limit or screening value with an increase in total bilirubin ≥ 2 times the upper normal limit or screening value)  • Pregnancies are also defined as IREs, although normal pregnancy is not an AE, it will mandate study drug discontinuation and must be reported on an immediately reportable event (IRE) form to OAPI.  Pregnancy will only be documented on the AE-CRF if there is an abnormality or complication. The investigator must immediately report any serious adverse event (SAE), potential Hy’s law cases, or confirmed pregnancy, by [CONTACT_123274] [INVESTIGATOR_123218] [IP_ADDRESS] after either the investigator or site personnel become aware of the event.  An IRE form must be completed and sent by [CONTACT_123275] [INVESTIGATOR_874] 24 hours of knowledge of the event by [CONTACT_779].  (Please note that the IRE form is NOT the AE CRF.) Non-serious events that require discontinuation of study drug (including laboratory abnormalities) should be reported to OAPI [INVESTIGATOR_874] [ADDRESS_138667] be completed and sent by [CONTACT_123275]. 
Protocol  COL.AOM.2013.002 
 
Page 61 of 76 
Final Protocol: [ADDRESS_138668]. POTENTIAL HY’S LAW CASES For a subject that experiences an elevation in AST or ALT that is ≥ 3 times the upper limit of normal (ULN) or whose levels increase ≥ 3 times their initial screening value, a total bilirubin level should also be evaluated.  If the total bilirubin is ≥ [ADDRESS_138669] or ≥ 2 times their screening value, complete an IRE form with all values listed and also report as an AE on the CRF. [IP_ADDRESS] Reporting of Pregnancy and Exposure to Study Drug Through Breastfeeding During the trial, all women of childbearing potential should be instructed to contact [CONTACT_26819], but no later than [ADDRESS_138670] they might be pregnant (e.g., missed or late menstrual cycle). If a subject or investigator suspects that the subject may be pregnant prior to study drug administration, the study drug administration must be withheld until the results of serum pregnancy tests are available.  If the pregnancy is confirmed, the subject must not receive the study drug and must not be enrolled in the study.  If pregnancy is suspected while the subject is taking study drug, the study drug must be withheld immediately (if reasonable, taking into consideration any potential withdrawal risks) until the result of the pregnancy is known.  If pregnancy is confirmed, the study drug will be permanently discontinued in an appropriate manner (e.g., dose tapering if necessary for subject safety) and the subject withdrawn from the study.  Exceptions to study discontinuation may be considered for life-threatening conditions only after consultations with OAPI’s Clinical Safety and Pharmacovigilance Department (see Section [IP_ADDRESS] for contact [CONTACT_3031]). The investigator must immediately notify OAPI [INVESTIGATOR_123219], including for [ADDRESS_138671] Pregnancy Surveillance Form(s) for monitoring the outcome of the pregnancy. Protocol required procedures for trial discontinuation and follow-up must be performed on the subject unless contraindicated by [CONTACT_8663] (e.g., x-ray studies).  Other appropriate pregnancy follow-up procedures should be considered if indicated.  In addition, the investigator must report to OAPI, on appropriate Pregnancy Surveillance Form(s), follow-up information regarding the course of the pregnancy, including perinatal and neonatal outcome.  Infants will be followed for a minimum of 6 months. [IP_ADDRESS] Reporting of Safety Information and Other Events of Interest All non-serious AEs will be reported to OAPI [INVESTIGATOR_123220]. 
Protocol  COL.AOM.2013.002 
 
Page 62 of 76 
Final Protocol: 29 July 2013 REPORTING OF ADVERSE EVENTS ASSOCIATED WITH STUDY DRUG OVERDOSE, MISUSE, ABUSE, OR MEDICATION ERROR Safety Information is defined as any information from any source containing information such as: ● Adverse event or suspi[INVESTIGATOR_123221] ● Lack of efficacy ● Overdose, abuse, misuse (even without resulting adverse reaction) ● Medication error ● Exposure during pregnancy or lactation (including uneventful) and reports where the embryo or fetus may have been exposed to medicinal products (either through maternal exposure or transmission of a medicinal product via semen following paternal exposure) ● Counterfeit product ● Transfer of infectious disease by [CONTACT_123276] ● Product complaint report which includes medically important information ● Pediatric use ● Occupational exposure  ● Off-label use Adverse events associated with study drug overdose, misuse, abuse, and medication error refer to AEs associated with uses of the study drug outside of that specified by [CONTACT_760].  Overdose, misuse, abuse, and medication error are defined as follows: Overdose Accidental or intentional use of the study drug in an amount higher than the protocol-defined dose  Misuse Intentional and inappropriate use of study drug not in accordance with the prescribed or authorized dose, route of administration, or indication(s) or use of prescription-only study drug without a prescription  Abuse Sporadic or persistent intentional excessive use of study drug accompanied by [CONTACT_123277], subject, or consumer.  Such events may be related to professional practice, healthcare products, procedures, and systems including prescribing; order communication; product labeling, 
Protocol  COL.AOM.2013.002 
 
Page 63 of 76 
Final Protocol: 29 July 2013 packaging, and nomenclature; compounding; dispensing; distribution; administration; education; monitoring; and use. All AEs associated with an overdose should be captured on the CRF.  Adverse events associated with overdose, misuse, abuse, or medication error should be reported using the procedures detailed in Reporting of Serious Adverse Events (Section [IP_ADDRESS]) even if the AEs do not meet serious criteria.  Abuse is always to be captured as an AE.  If the AE associated with an overdose, misuse, abuse, or medication error does not meet serious criteria, it must still be reported using the SAE form and in an expedited manner but should be noted as nonserious on the SAE form and the CRF. [IP_ADDRESS] Regulatory Reporting of Adverse Events Adverse events will be reported by [CONTACT_1720] a third party acting on behalf of the investigator to regulatory authorities in compliance with the law and established guidance and will be reported to OAPI [CONTACT_2669] [ADDRESS_138672] will be copi[INVESTIGATOR_123222].   9.5.6 Completion/Discontinuation of Subjects A subject may elect to discontinue the study at any time for any reason without prejudice.  All subjects who discontinue the study are to complete the study’s early discontinuation procedures indicated in the Schedules of Assessments (Table 4 through Table 7) whenever possible. The investigator will promptly explain to the subject involved that the study will be discontinued for that subject and provide appropriate medical treatment and other necessary measures for the subject.  A subject who has ceased to return for visits will be followed up by [CONTACT_2319], phone, or other means to gather information such as the reason for failure to return, the status of treatment compliance, the presence or absence of AEs, and clinical courses of signs and symptoms.  This information will be recorded in the CRF. Subjects who discontinue early from the study will be discontinued for one of these primary reasons: AE(s), lost to follow-up, subject choice, inadequate therapeutic effect, withdrawal of consent, pregnancy, study terminated, or other (to be specified).  In addition to the primary reason, the subject may indicate one or more secondary reasons for discontinuation. A subject removed from the study for any reason may be replaced. 
Protocol  COL.AOM.2013.002 
 
Page 64 of 76 
Final Protocol: [ADDRESS_138673] whether he/she has received medical care by [CONTACT_85856].  When the subject is going to receive medical care by [CONTACT_20427], the investigator, with the consent of the subject, will inform the other physician that the subject is participating in the clinical study. 9.6 DATA QUALITY ASSURANCE 9.6.1 Monitoring The OAPI [INVESTIGATOR_123223], legal, and scientific obligations to follow this trial in a detailed and orderly manner in accordance with established research principles, the ICH GCP Guideline, FDA regulations and applicable regulatory requirements and local laws.  As part of a concerted effort to fulfill these obligations (maintain current personal knowledge of the progress of the trial), OAPI's monitors may visit the site during the trial, as well as communicate frequently via telephone and written communications.   9.6.2 Auditing The OAPI [INVESTIGATOR_123224] (or representative) may conduct trial site audits.  Audits will include, but are not be limited to, drug supply, presence of required documents, the informed consent process, and comparison of CRFs with source documents.  The investigator agrees to participate with audits. Regulatory authorities may inspect the investigator during or after the trial.  The investigator will cooperate with such inspections and will contact [CONTACT_123278]. 9.6.[ADDRESS_138674]’s data has been entered into the database and no data queries are outstanding. 9.[ADDRESS_138675] been released.  Statistical analyses will be performed using SAS software or other validated statistical software as required.  Details of the statistical analyses will be included in a separate statistical analysis plan (SAP). 9.7.1 Statistical and Analytical Plans The statistical analyses of study data are described in this section.  Additional details of the analytical plan will be provided in the SAP, which will be finalized before database lock. 
Protocol  COL.AOM.2013.002 
 
Page 65 of 76 
Final Protocol: 29 July 2013 [IP_ADDRESS] Primary Endpoint(s) The primary efficacy endpoint is change from Phase C baseline in prefrontal white matter FA measured by [CONTACT_123251]-MRI. The primary time point will be the Week 52 assessment.  Secondary Endpoint(s) The secondary efficacy endpoints will include: • Change from Phase C baseline in volumes by [CONTACT_5019]-resolution MRI.  This variable will be analyzed using the methods employed for the primary endpoint. • Change from Phase C baseline in Water-BPF by [CONTACT_9268].  This variable will be analyzed using the methods employed for the primary endpoint. • Changes from Phase C baseline in schizophrenia-related instrument scores, if appropriate.  These variables will be analyzed using the methods employed for the primary endpoint. • Changes from Phase C baseline in neuropsychological measures.  These variables will be analyzed using the methods employed for the primary endpoint. [IP_ADDRESS] Exploratory Endpoint(s) Exploratory endpoints such as proton metabolite measurements by [CONTACT_123279].  Additional analyses will be performed as appropriate. [IP_ADDRESS] Definitions of Analysis Sets Three analysis populations will be considered in this study, safety, intent-to-treat (ITT), and per protocol (PP) populations.   • Safety population:  includes all subjects with any safety assessments • ITT population:  includes all subjects with some Phase C baseline and post-baseline efficacy assessments • PP population includes:  all ITT subjects without major protocol deviations Unless otherwise stated, the primary safety analyses will be based on the safety population and the primary efficacy and pharmacodynamic analyses will be based on the ITT population.  The primary comparisons will be made between the SOC oral antipsychotic arm and the aripi[INVESTIGATOR_123225] C. [IP_ADDRESS] Subject Disposition Descriptive statistics will be utilized.  By-subject listings and summary tables will be provided. [IP_ADDRESS] Demographic and Other Baseline Characteristics Descriptive statistics will be utilized.  By-subject listings and summary tables will be provided. 
Protocol  COL.AOM.2013.002 
 
Page 66 of 76 
Final Protocol: 29 July 2013 [IP_ADDRESS] Prior and Concomitant Therapy All investigator terms for medications recorded in the CRF will be coded to an 11-digit code using the World Health Organization Drug Dictionary (WHO DD).  The number (percentage) of subjects who took prior and concomitant medications will be summarized by [CONTACT_1570], Anatomical Therapeutic Chemical (ATC) class (i.e., nervous system class and therapeutic class), and WHO DD preferred term.  Prior medications will be defined as medications that stopped before the first dose of study drug.  Concomitant medications will be defined as medications that (1) started before the first dose of study drug and were continuing at the time of the first dose of study drug, or (2) started on or after the date of the first dose of study drug up to [ADDRESS_138676]’s last dose.  All medications will be presented in subject data listings. [IP_ADDRESS] Safety Analyses All safety analyses will be performed on the Safety Analysis Set.  Safety data, presented by [CONTACT_123280] “as treated” basis using descriptive statistics (e.g., n, mean, standard deviation, median, minimum, maximum for continuous variables; n [%] for categorical variables).  Safety variables include physical examinations, neurologic evaluations, treatment-emergent adverse events (TEAEs), clinical laboratory parameters, vital signs, 12-lead ECG results, and injection site reactions.  Study Day [ADDRESS_138677] dose of study drug. [IP_ADDRESS].[ADDRESS_138678] listings and summary tables will be provided. [IP_ADDRESS].2 Adverse Events The AE verbatim descriptions (investigator terms from the CRF) will be classified into standardized medical terminology using the Medical Dictionary for Regulatory Activities (MedDRA).  Adverse events will be coded to the MedDRA lower level term (LLT) closest to the verbatim term.  The linked MedDRA preferred term (PT) and primary system organ class (SOC) are also captured in the database. A TEAE is defined as an AE that emerges during treatment, having been absent at pretreatment (Baseline) or  ● Reemerges during treatment, having been present at pretreatment (Baseline) but stopped before treatment, or  ● Worsens in severity during treatment relative to the pretreatment state, when the AE is continuous. Only those AEs that were treatment emergent will be included in summary tables.  All AEs, treatment emergent or otherwise, will be presented in subject data listings. Treatment-emergent AEs (TEAEs) will be summarized by [CONTACT_6654].  The incidence of TEAEs will be reported as the number (percentage) of subjects with TEAEs by [CONTACT_3592].  A subject will be counted only once within a SOC and PT, even if the subject 
Protocol  COL.AOM.2013.002 
 
Page 67 of 76 
Final Protocol: 29 July 2013 experienced more than one TEAE within a specific SOC and PT.  The number (percentage) of subjects with TEAEs will also be summarized by [CONTACT_764] (mild, moderate, or severe). The number (percentage) of subjects with TEAEs will also be summarized by [CONTACT_8792] (possibly related, probably related, and not related). The number (percentage) of subjects with treatment-related TEAEs will be summarized by [CONTACT_3592].  Treatment-related TEAEs include those events considered by [CONTACT_123281].  The number (percentage) of subjects with treatment-related TEAEs will also be summarized by [CONTACT_764] (mild, moderate, or severe). Adverse events will be summarized using the Safety Analysis Set.  The number of AEs and number and incidence (%) of subjects with AEs will be summarized by [CONTACT_9084]/dose level and overall.  To obtain the incidence (%), the number of subjects with at least 1 event and the percentage of subjects with AEs by [CONTACT_9313] (SOC) and by [CONTACT_11702] (PT) will be calculated.  Incidence (%) by [CONTACT_123282].  For clinically significant events, time of onset, and recovery will be reported. The number (percentage) of subjects with TEAEs leading to death will be summarized by [CONTACT_123283].  A subject data listing of all AEs leading to death will be provided. The number (percentage) of subjects with SAEs will be summarized by [CONTACT_123283].  A subject data listing of all SAEs will be provided. The number (percentage) of subjects with TEAEs leading to discontinuation from study drug will be summarized by [CONTACT_123283].  A subject data listing of all AEs leading to discontinuation from study drug will be provided. [IP_ADDRESS].3 Laboratory Values Summary statistics for changes from baseline and the incidence of potentially clinically significant values in the routine clinical laboratory measurements will be provided. [IP_ADDRESS].[ADDRESS_138679] listings will be provided for physical examination. Summary statistics for change from baseline and incidence of potentially clinically significant results in vital signs will be provided. [IP_ADDRESS].5 Electrocardiograms Mean change from baseline and incidence of clinically significant changes in ECG parameters will be calculated. 
Protocol  COL.AOM.2013.002 
 
Page 68 of 76 
Final Protocol: 29 July 2013 [IP_ADDRESS].6 Other Safety Analyses Summary statistics will be provided for the change from baseline in SAS, AIMS, and BARS when applicable.  Summary statistics for VAS score and injection site reaction will be provided when applicable.  Suicidality data collected on the C-SSRS will be summarized as appropriate. [IP_ADDRESS] Efficacy Analyses [IP_ADDRESS].1 Primary Efficacy Analysis The primary endpoint will be analyzed by [CONTACT_12359] (ANOVA) model with treatment effect.  The treatment effects, treatment differences, and the 95% confidence intervals of the treatment differences will be presented. [IP_ADDRESS].2 Secondary Efficacy Analyses The secondary endpoints will be analyzed by [CONTACT_12359] (ANOVA) model with treatment effect.  The treatment effects, treatment differences, and the 95% confidence intervals of the treatment differences will be presented. Correlations between the imaging parameters, especially the primary endpoints and the neuropsychological measures (e.g., reaction time) will be analyzed. [IP_ADDRESS].3 Exploratory Efficacy Analyses Exploratory endpoints such as proton metabolite measurements by [CONTACT_123279].  Additional analyses will be performed as appropriate. [IP_ADDRESS] Pharmacokinetic/Pharmacodynamic Analyses [IP_ADDRESS].1 Pharmacokinetic Analyses Not applicable. [IP_ADDRESS].2 Pharmacodynamic Analyses The PD endpoints will be analyzed by [CONTACT_12359] (ANOVA) model with treatment effect.  The treatment effects, treatment differences, and the 95% confidence intervals of the treatment differences will be presented. 9.7.2 Determination of Sample Size After screening subjects with schizophrenia will be randomized in a 2:1 (aripi[INVESTIGATOR_123104]:/SOC oral antipsychotics) ratio to the aripi[INVESTIGATOR_123105].  A sample size of 42 (28 in the depot arm and 14 in the oral arm) will provide 90% power to detect a treatment difference for the primary endpoint at a two-sided 5% significance level.  In the sample size calculation, it was assumed a treatment difference of 0.[ADDRESS_138680] deviation of 0.64.  Approximately 60 subjects with schizophrenia will be randomized (40 in the depot arm and 20 in the oral arm) to account for the expected dropouts.  Up to 20 normal healthy subjects will also be enrolled to serve as the control. 
Protocol  COL.AOM.2013.002 
 
Page 69 of 76 
Final Protocol: 29 July 2013 9.7.3 Interim Analysis No interim analysis is planned. [IP_ADDRESS] Data Safety Monitoring Board  In addition, a DSMB will be created in compliance with the University of Utah IRBs guidances.  [IP_ADDRESS].[ADDRESS_138681] privacy and data confidentiality, and will recommend added protections if necessary. [IP_ADDRESS].[ADDRESS_138682] adherence to the protocol’s procedures and study-drug compliance, and a summary of the completeness and quality of the data elements needed to characterize the subjects and their primary and secondary outcomes.  These reports will be used by [CONTACT_123284]’s data capture and management to support scientifically valid analysis.  The DSMB will make recommendations to improve data management as needed. The PI [INVESTIGATOR_123226], SAEs, and any subject deaths; and provide an unbiased written report of the event within 5 calendar days. The medical monitor will comment on the outcome of the AEs and relationship of the event to the study drug.  9.7.4 Other Statistical/Analytical Issues Not applicable. 9.7.5 Procedure for Revising the Statistical Analysis Plan If the SAP requires revision after the study starts, the investigator will determine how the revision impacts the study and how the revision should be implemented.  The details of the revision will be documented and described in the clinical study report. 
Protocol  COL.AOM.2013.002 
 
Page 70 of 76 
Final Protocol: [ADDRESS_138683] accordance with the protocol (refer to ICH E6, Section 4.5). 10.[ADDRESS_138684]’s corresponding original medical records (source documents) are to be fully available for review by [CONTACT_456]’s representatives at regular intervals.  These reviews verify adherence to study protocol and data accuracy in accordance with local regulations.  All records at the site are subject to inspection by [CONTACT_123285]. In accordance with ICH E6, Section 1.52, source documents include, but are not limited to the following: ● Clinic, office, or hospi[INVESTIGATOR_1332] ● Copi[INVESTIGATOR_123227] ● Recorded data from automated instruments such as IxRS, x-rays, and other imaging reports, (e.g., sonograms, CT scans, magnetic resonance images, radioactive images, ECGs, rhythm strips, EEGs, polysomnographs, pulmonary function tests) regardless of how these images are stored, including microfiche and photographic negatives ● Pain, quality of life, or medical history questionnaires completed by [CONTACT_1766] ● Records of telephone contacts 
Protocol  COL.AOM.2013.002 
 
Page 71 of 76 
Final Protocol: 29 July 2013 ● Diaries or evaluation checklists ● Drug distribution and accountability logs maintained in pharmacies or by [CONTACT_2710] ● Laboratory results and other laboratory test outputs (e.g., urine pregnancy test result documentation and urine dip-sticks) ● Correspondence regarding a study subject’s treatment between physicians or memoranda sent to the IRBs ● CRF components (e.g., questionnaires) that are completed directly by [CONTACT_123286] 10.[ADDRESS_138685] the corresponding source documents. 10.6 RETENTION OF RECORDS The circumstances of completion or termination of the study notwithstanding, the investigator is responsible for retaining all study documents, including but not limited to the protocol, copi[INVESTIGATOR_3110], the Investigator's Brochure, and regulatory agency registration documents (e.g., Form FDA 1572, ICFs, and IRB correspondence).  The site should plan to retain study documents for the length of time agreed upon in the study contract. It is requested that at the completion of the required retention period, or should the investigator retire or relocate, the investigator contact [CONTACT_123287], allowing OAPI [INVESTIGATOR_123228]. 10.7 AUDITING PROCEDURES AND INSPECTION In addition to the routine monitoring procedures, the OAPI [INVESTIGATOR_123229]’s SOPs to evaluate compliance with the principles of ICH GCP and all applicable local regulations.  If a government regulatory authority requests an inspection during the study or after its completion, the investigator must inform OAPI [INVESTIGATOR_97318]. 
Protocol  COL.AOM.2013.002 
 
Page 72 of 76 
Final Protocol: [ADDRESS_138686] be reviewed and approved in writing by [CONTACT_123287] [INVESTIGATOR_123230]/investigator.  The review is aimed at protecting OAPI's proprietary information existing either at the date of the commencement of the study or generated during the study. The detailed obligations regarding the publication of any data, material results, or other information, generated or created in relation to the study shall be set out in the agreement between the investigator and OAPI, as appropriate. 10.9 DISCLOSURE AND CONFIDENTIALITY The contents of this protocol and any amendments and results obtained during the study should be kept confidential by [CONTACT_093], the investigator’s staff, and the IRB and will not be disclosed in whole or in part to others, or used for any purpose other than reviewing or performing the study, without the written consent of OAPI.  No data collected as part of this study will be used in any written work, including publications, without the written consent of OAPI.  These obligations of confidentiality and non-use shall in no way diminish such obligations as set forth in either the Confidentiality Agreement or Clinical Study Agreement executed between OAPI [INVESTIGATOR_123231]/investigator. All persons assisting in the performance of this study must be bound by [CONTACT_123288]-use set forth in either the Confidentiality Agreement or Clinical Study Agreement executed between the institution/investigator and OAPI. 10.10 DISCONTINUATION OF STUDY OAPI [INVESTIGATOR_123232].  If a study is prematurely terminated or suspended, OAPI [INVESTIGATOR_123233]/institutions and the investigator will inform the regulatory authorities of the termination or suspension and the reason(s) for the termination or suspension.  The IRB will also be informed promptly and provided the reason(s) for the termination or suspension by [CONTACT_093]/institution, as specified by [CONTACT_8146](s). The investigator reserves the right to discontinue the study should his/her judgment so dictate.  If the investigator terminates or suspends a study without prior agreement of OAPI, the investigator should inform the institution where applicable, and the investigator/institution should promptly inform OAPI [INVESTIGATOR_123234] a detailed written explanation of the termination or suspension.  Study records must be retained as noted above. 
Protocol  COL.AOM.2013.002 
 
Page 73 of 76 
Final Protocol: [ADDRESS_138687] 1 DeLisi LE, Sakuma M, Tew W, Kushner M, Hoff AL, Grimson R.  Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res.  Jul 4 1997; 74(3):129-140. 2 Dorph-Petersen KA, Pi[INVESTIGATOR_123235], Perel JM, Sun Z, Sampson AR, Lewis DA.  The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapi[INVESTIGATOR_123236]. Neuropsychopharmacology.  Sep 2005; 30(9):1649-1661. 3 van Haren NE, Hulshoff Pol HE, Schnack HG, et al.  Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology.  Oct 2007; 32(10):2057-2066. 4 Molina V, Reig S, Sanz J, et al.  Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypi[INVESTIGATOR_123237]. Schizophr Res.  Dec 1 2005; 80(1):61-71. [ADDRESS_138688]-epi[INVESTIGATOR_16743]. Arch Gen Psychiatry.  Apr 2005; 62(4):361-370. [ADDRESS_138689]-epi[INVESTIGATOR_34923]: differential impact on white matter myelination trajectory. Schizophr Res.  Oct 2011; 132(1):35-41. 7 Kennedy KM, Raz N.  Aging white matter and cognition: Differential effects of regional variations in diffusion properties on memory, executive functions, and speed. Neuropsychologia.  Feb 2009; 47(3):916-927. 8 Gulani V, Sundgren PC.  Diffusion tensor magnetic resonance imaging. J Neuroophthalmol.  Mar 2006; 26(1):51-60. 9 Grieve SM, Williams LM, Paul RH, Clark CR, Gordon E.  Cognitive aging, executive function, and fractional anisotropy: a diffusion tensor MR imaging study. AJNR Am J Neuroradiol.  Feb 2007; 28(2):226-235. 10 Madden DJ, Whiting WL, Huettel SA, White LE, MacFall JR, Provenzale JM.  Diffusion tensor imaging of adult age differences in cerebral white matter: relation to response time. Neuroimage.  Mar 2004; 21(3):1174-1181. [ADDRESS_138690] bound pool fraction mappi[INVESTIGATOR_123238].  Magn Reson Med. Sep 2011; 66(3):717-724. 
Protocol  COL.AOM.2013.002 
 
Page 74 of 76 
Final Protocol: 29 July 2013 12 Stikov N, Perry LM, Mezer A, et al.  Bound pool fractions complement diffusion measures to describe white matter micro and macrostructure.  Neuroimage.  Jan 15 2011; 54(2):1112-1121. [ADDRESS_138691], Spi[INVESTIGATOR_6942] M, Lundbom N.  Relaxometry of brain: why white matter appears bright in MRI. Magn Reson Med.  Jun 1990; 14(3):482-495. 14 Ou X, Sun SW, Liang HF, Song SK, Gochberg DF.  Quantitative magnetization transfer measured pool-size ratio reflects optic nerve myelin content in ex vivo mice.  Magn Reson Med.  Feb 2009; 61(2):364-371. 15 Schmierer K, Tozer DJ, Scaravilli F, et al.  Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain.  J Magn Reson Imaging.  Jul 2007; 26(1):41-51. 16 Rushton WA. A theory of the effects of fibre size in medullated nerve.  J  Physiol. Sep 1951; 115(1):101-122. 17 Waxman SG.  Integrative properties and design principles of axons.  Int Rev Neurobiol. 1975; 18:1-40. 18 Baumann N, Pham-Dinh D.  Biology of oligodendrocyte and myelin in the mammalian central nervous system.  Physiol Rev. Apr 2001; 81(2):871-927. 19 Dager SR, Corrigan NM, Richards TL, Posse S.  Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders.  Topi[INVESTIGATOR_99300] :  TMRI.  Apr 2008; 19(2):81-96. [ADDRESS_138692].  GABA, gamma-hydroxybutyric acid, and neurological disease.  Annals of neurology.  2003; [ADDRESS_138693] 6:S3-12. 21 Sanacora G, Mason GF, Rothman DL, Krystal JH.  Increased occipi[INVESTIGATOR_123239].  Am J Psychiatry. Apr 2002; 159(4):663-665. 22 Petroff OA, Errante LD, Rothman DL, Kim JH, Spencer DD.  Neuronal and glial metabolite content of the epi[INVESTIGATOR_123240].  Annals of neurology. Nov 2002; 52(5):635-642. 23 Streeter CC, Hennen J, Ke Y, et al. Prefrontal GABA levels in cocaine-dependent subjects increase with pramipexole and venlafaxine treatment. Psychopharmacology (Berl). Nov 2005;182(4):516-526. 24 McLoughlin GA, Ma D, Tsang TM, et al.  Analyzing the effects of psychotropic drugs on metabolite profiles in rat brain using 1H NMR spectroscopy.  J Proteome Res. Apr 2009; 8(4):1943-1952. 
Protocol  COL.AOM.2013.002 
 
Page 75 of 76 
Final Protocol: 29 July 2013 25 Chanraud S, Zahr N, Sullivan EV, Pfefferbaum A. MR diffusion tensor imaging: a window into white matter integrity of the working brain. Neuropsychol Rev. Jun 2010;20(2):209-225. 26 Prescot AP, Locatelli AE, Renshaw PF, Yurgelun-Todd DA.  Neurochemical alterations in adolescent chronic marijuana smokers: a proton MRS study. Neuroimage.  Jul 1 2011; 57(1):69-75. 27 Aripi[INVESTIGATOR_123241]. 13.  BMS Document Control, 2009. 15[PHONE_2801] 11.0). [ADDRESS_138694], Ingenito GG, Zimbroff DL, et al.  Efficacy and safety of aripi[INVESTIGATOR_123242].  J Clin Psychiatry. 2002; 63:763-71 29 Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al.  Aripi[INVESTIGATOR_4253],  an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.  Arch Gen Psychiatry.  2003; 60:681-90 30 Carson WH.  A multicenter, randomized, double-blind, placebo-controlled study of three fixed doses of aripi[INVESTIGATOR_123243].  Bristol-Myers Squibb Company Study No. CN138001/Report BMS Document Control No. 930000317, 2001 31 Carson, WH. A multicenter, randomized, double-blind, placebo-controlled, 26 week study of a fixed dose of aripi[INVESTIGATOR_123244].  Bristol-Myers Squibb Company Study No. CN138047/Report BMS Document Control No. 930000855, 2001 32 Pi[INVESTIGATOR_123245], C.W., Saha AR, Torbeyns AF, Stock EG, Ingenito GG, et al. Aripi[INVESTIGATOR_123246]: a placebo-controlled 26-week study. J Clin Psychiatry.  2003. 64(1046-56). [ADDRESS_138695], Saha A, Carson WH, Ali M, et al.  Efficacy and safety of aripi[INVESTIGATOR_123247]. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.  Int J Neuropsychopharmacol.  2003; 6:325-7. 35 Marcus R.  A Prospective, Multicenter, Open-Label Study of Aripi[INVESTIGATOR_123248] (Broad 
Protocol  COL.AOM.2013.002 
 
Page 76 of 76 
Final Protocol: 29 July 2013 Effectiveness Trial with Aripi[INVESTIGATOR_4253] - BETA).  Bristol-Myers Squibb Company Study No. CN138100, [ADDRESS_138696] of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripi[INVESTIGATOR_4253]:  (STAR) study. . Eur Psychiatry, 2007. 22(433-43). 38 Tandon R, D.R., Han J, Li H, Frangou S, Dursun S for the IAQ Validation Study Group.  Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder.  Psychiatry Research, 2005.  136(211-21). [ADDRESS_138697], Oren DA.  Efficacy and safety of intramuscular aripi[INVESTIGATOR_123249]:  A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry, 2007. 68:111. 40 Nyalis M, Mallikaarjun S.  An open-label parallel arm multiple dose tolerability, pharmacokinetics and safety study in adult patients with schizophrenia following administration of aripi[INVESTIGATOR_123250].  Otsuka Clinical Study Report for Protocol 31-05-244, issued 27 May 2009, amended 17 Jul 2009 41 Vieta E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade R.  Effectiveness of aripi[INVESTIGATOR_4253] v. haloperidol in acute bipolar mania:  Double-blind, randomised, comparative 12-week trial.  Br J Psychiatry.  2005; 187:235-42. 42 .Schulte RF and Boesiger P.  ProFit:  two-dimensional prior-knowledge fitting of J-resolved spectra.  NMR Biomed.  2006 Apr; 19(2):255-63. [ADDRESS_138698] integrity in healthy aging and mild cognitive impairment:  a DTI follow-up study.  J Alzheimers Dis.  2010; 22(2):507-22.    